• Home
  • » 
  • Reports
  • » 
  • Drug Adherence Enhancement Market: Devices and Applications | Industry Analysis | Market Size | 2030

Global Drug Adherence Market: Focus on Smart Delivery Devices (Smart Inhalers, Injectors, Wearable Injectors, Pills) and Smart Accessories (Medication Dispensers, Pill Bottles / Boxes, Blister Packs)

  • Lowest Price Guaranteed From USD 3,499

  • Published
    October 2018

  • Pages
    450

  • View Count
    8192

  • Buy Now

Example Insights

 

Report Description

Poor adherence to prescribed medications is a growing concern in the healthcare industry and is believed to be associated with negative health outcomes, inflated medical expenses, loss in productivity and, in certain cases, proves fatal as well. It has been estimated that, of the ~4 billion annual prescriptions filled by the retailers in the US, approximately 50% are not taken by patients in accordance to physicians’ instructions. According to the US Centers for Disease Control and Prevention (CDC), failure to comply to prescribed treatment regimens has been identified as the cause of 125,000 premature deaths, up to 69% of all rehospitalizations, and results in approximately USD 100-300 billion worth of avoidable annual healthcare spending. Further, the US pharmaceutical industry alone is estimated to suffer a loss of approximately USD 188 billion per year, due to low adherence to prescribed medications.

Lack of compliance to therapy is particularly prevalent among elderly patients suffering from chronic clinical conditions, such as cardiovascular disorders, metabolic disorders (e.g., diabetes), neurological and central nervous system related disorders (e.g., multiple sclerosis and Parkinson’s disease) and respiratory disorders (e.g., asthma and chronic obstructive pulmonary disease). It is estimated that overall cost of treatment for non-adherent patients is at least twice as high as patients who adhere to recommended therapy regimens. Studies have demonstrated that every one percent improvement in medication adherence can help the US healthcare industry save up to USD 2 billion, resulting in an increase in pharmaceutical revenues by ~USD 4 billion. As a result, several strategies have been / are being developed by pharmaceutical developers and healthcare providers to improve medication adherence. Such initiatives have been strengthened owing to the availability of connected devices and other digital solutions, which allow patients / healthcare providers to closely monitor and improve drug adherence.

 

Scope of the Report

The ‘Global Drug Adherence Market: Focus on Smart Delivery Devices (Smart Inhalers, Injectors, Wearable Injectors, Pills) and Smart Accessories (Medication Dispensers, Pill Bottles / Boxes, Blister Packs)’ report features an extensive study of the current landscape and future outlook of the growing market for smart medication adherence devices that are either already commercialized or under development. This burgeoning field presently offers a lot of opportunities to innovation-driven start-ups and investors. Amongst other elements, the report features:

  • A discussion on the current market landscape of smart drug delivery devices for medication adherence (which include smart inhalers, smart injectors, smart wearable injectors and smart pills), featuring information on the developers, along with details on key product specifications, namely audio / visual reminders, connectivity features (USB connection, Bluetooth and / or cellular network), availability of companion mobile application(s) and / or  web portal(s), data storage / cloud platform options, and availability of battery backup / rechargeable batteries.
  • A discussion on the current market landscape of smart accessory devices for medication adherence (including smart medication dispensers, smart pill bottles / caps, smart pill boxes and smart blister packs), featuring information on the various developers, along with details on key product specifications. The section also presents a list of compliance packaging systems, along with information on their developers.
  • A summary of the various guidelines issued by regulatory authorities to govern the development and approval of combination products (drugs and smart devices) across different geographical regions.
  • Detailed profiles of some of the leading players in the industry (based on a proprietary shortlisting criteria), highlighting a brief overview of the company, financial information (if available), details related to its products / offerings, clinical trial results, recent developments and a comprehensive future outlook.
  • Detailed case studies on the most common chronic disease indications, featuring disease epidemiology, an overview of the economic burden imposed due to non-adherence to prescribed treatment regimens and a history of drug development efforts along with details on the evolution of delivery devices / strategies for improving therapy adherence.
  • A comprehensive competitiveness analysis of connected smart drug delivery systems and smart accessory systems on the basis of supplier power and key product specifications.
  • An analysis of funding and investments made in companies focused in this domain; the analysis covers information on seed financing, venture capital financing, debt financing, other equity financing and grants / awards received by these companies.
  • An analysis of the partnerships that have been forged between companies in the recent past, covering acquisitions, treatment optimization agreements, distribution agreements, manufacturing and supply agreements, product improvement agreements, product development agreements, product commercialization agreements, licensing agreements, service alliances and other relevant deals inked in the period 2010-2018. It also highlights the number of intercontinental and intracontinental deals signed in the aforementioned time period.
  • A list of standalone mobile applications that have been developed / are being developed to enable patients to adhere to prescribed medication regimens, along with the USFDA’s regulations related to such applications. It also includes details on the various articles / publications that have reported the results achieved by using mobile applications for improving medication adherence among patients.

One of the key objectives of the report was to understand the primary growth drivers and estimate the future size of the market. Based on various parameters, such as target consumer segments, likely adoption rates and expected pricing, we have provided an informed estimate on the likely evolution of the market in the short to mid-term and long term, for the period 2018-2030. We have segmented the market by type of solution (smart drug delivery devices and smart accessory devices), type of product (smart inhalers, smart injectors, smart wearable injectors, smart pills, smart medication dispensers, smart pill bottles / caps and boxes, smart blister packs and others), therapeutic areas (metabolic disorders, cardiovascular disorders, neurological and central nervous system related disorders, respiratory disorders, and others), route of administration (oral, injectable, inhalable and others) and geography (North America, Europe, Asia-Pacific and rest of the world). To account for the uncertainties associated with the development of these novel therapies and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market’s evolution.

The opinions and insights presented in the report were also influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following individuals:

  • Bernard Vrijens (Chief Executive Officer, AARDEX Group)
  • Spencer Waugh (Chief Executive Officer, AceAge)
  • Josh Stein (Chief Executive Officer, AdhereTech)
  • Duilio Macchi (Chief Executive Officer, Amiko Digital Health)
  • Gaurav Patel (Chief Technical Officer, Cognita Labs)
  • Tina Valbh (Strategy and Business Development (Advisor), etectRx)
  • Jonathan Sacks (Chief Executive Officer and Chairman, PharmAdva)
  • Timo Heikkilä (Co-Founder and Chief Operating Officer, Popit Technologies)
  • Moore Greenberg (Founder, Wealth Taxi)
  • Anonymous (Small-sized company)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Contents

Chapter 2 provides an executive summary of the insights captured during our research. It offers a high-level view on the likely evolution of smart / connected devices that are being developed for improving medication adherence among patients.

Chapter 3 provides a general overview about medication adherence and the various methods / parameters used to measure and track patient compliance to prescribed therapeutic regimens. It also includes brief discussion on various types of non-adherence to therapy exhibited by patients and different factors that are considered to be responsible for such practices. In addition, the chapter features a detailed discussion on how non-adherence to therapy is impacting the health of patients and the overall healthcare industry. Further, it includes a brief discussion on various traditional and modern strategies for overcoming poor therapy adherence in patients. The chapter also provides information on the different initiatives that have been undertaken by various organizations to promote medication adherence.

Chapter 4 includes information on over 60 smart drug delivery devices that are either commercialized or under different stages of development for improving medication adherence. The chapter includes the information on the developer companies and the type of smart drug delivery product they offer; these include smart inhalers, smart injectors, smart wearable injectors, smart pills and other such devices. In addition, the chapter includes an analysis based on key product specifications, namely audio / visual reminders, connectivity features (USB connection, Bluetooth and / or cellular network), availability of companion mobile application, and companion web portal, data storage / cloud platform options and availability of battery backup / rechargeable battery.

Chapter 5 includes information on over 70 smart accessory devices that are either commercialized or under different stages of development for improving medication adherence. The chapter includes information on the developer companies and the type of smart accessory product they offer; these include smart medication dispensers, smart pill bottles / caps, smart pill boxes, smart blister packs and others. In addition, the chapter includes an analysis on key product specifications, namely audio / visual reminders, connectivity features (USB connection, Bluetooth, Wi-Fi and / or cellular network), availability of companion mobile application, and companion web portal, data storage / cloud platform options and availability of battery backup / rechargeable battery. Further, the chapter includes a brief overview on compliance packaging and a list of key players with expertise in this domain.

Chapter 6  provides information on various guidelines issued by regulatory authorities to govern the development and approval of combination products (drugs and smart devices) across different geographical regions such as North America, Europe, Latin America, Asia Pacific and the Middle East.

Chapter 7 features detailed profiles of some of the leading stakeholders in the smart drug delivery systems market. Each profile includes a brief overview of the company, financial information (if available), details related to its products / offerings, clinical trial results, recent developments and a comprehensive future outlook.

Chapter 8 features detailed profiles of some of the leading stakeholders in the smart accessory systems market. Each profile includes a brief overview of the company, financial information (if available), details related to its products / offerings, clinical trial results, recent developments and a comprehensive future outlook.

Chapter 9 features case studies on the most common disease indications across metabolic disorders, respiratory disorders and autoimmune disorders. Each case study features a detailed description of the disease, its epidemiology, an overview of the economic burden imposed due to non-adherence to prescribed treatments for the disease and history of drug development along with the evolution of delivery devices / strategies focused on improving therapy adherence.

Chapter 10 presents a product competitiveness analysis of all connected smart drug delivery systems and smart accessory systems on the basis of supplier power and key product specifications. The analysis was designed to enable stakeholder companies to compare their existing capabilities within and beyond their respective peer groups and identify opportunities to achieve a competitive edge in the industry.

Chapter 11 provides information on the funding and investments that have been made in both smart drug delivery systems and smart accessory systems in the recent past. The chapter includes details on various types of capital investments, such as seed financing, venture funding, debt financing and grants, received by companies, highlighting the growing interest of the venture capital community and other strategic investors in this domain.

Chapter 12 features an analysis of the recent collaborations and partnerships that have been inked amongst players in this market, covering several partnership models, namely  acquisitions, treatment optimization agreements, distribution agreements, manufacturing and supply agreements, product improvement agreements, product development agreements, product commercialization agreements, licensing agreements, service alliances and others, that have been adopted by industry stakeholders in this domain. It includes a world map representation of all the deals inked in this field in the period 2010-2018, highlighting both intercontinental and intracontinental partnership activity.

Chapter 13 provides a brief overview of the increasing prominence of mobile applications in the healthcare industry and the various regulations laid down by the USFDA for such applications. It includes a list of applications that are available at Google Play Store for helping patients adhere to prescribed medication regimens. The chapter also provides information on the various articles / publications, featuring results of studies aimed to demonstrate the benefits of using mobile applications for improving medication adherence among patients.

Chapter 14 presents a comprehensive market forecast, highlighting the future potential of the market till 2030 based on multiple parameters, such as prices of novel solutions, indication / region specific adoption trends, and competitive landscape. We have provided an informed estimate on the likely evolution of smart drug delivery devices and smart accessory devices. In addition, we have segmented the market by type of product (smart inhalers, smart injectors, smart wearable injectors, smart pills, smart medication dispensers, smart pill bottles / caps and boxes, smart blister packs and others), therapeutic areas (metabolic disorders, cardiovascular disorders, neurological and central nervous system related disorders, respiratory disorders and others), route of administration (oral, injectable, inhalable and others) and geography (North America, Europe, Asia-Pacific and rest of the world).

Chapter 15 summarizes the overall report.  The chapter provides a list of the key takeaways and presents our independent opinion on the medication adherence market, specific to smart drug delivery systems and smart accessory systems, based on the research and analysis described in the previous chapters.

Chapter 16 is a collection of interview transcripts of the discussions that were held with key stakeholders in this market. The chapter provides details of interviews held with Bernard Vrijens (Chief Executive Officer, AARDEX Group), Spencer Waugh (Chief Executive Officer, AceAge), Josh Stein (Chief Executive Officer, AdhereTech), Duilio Macchi (Chief Executive Officer, Amiko Digital Health), Gaurav Patel (Chief Technical Officer, Cognita Labs), Tina Valbh (Strategy and Business Development (Advisor), etectRx), Jonathan Sacks (Chief Executive Officer and Chairman, PharmAdva), Timo Heikkilä (Co-Founder and Chief Operating Officer, Popit Technologies), Moore Greenberg (Founder, Wealth Taxi) and Anonymous (Small-sized company)

Chapter 17 is an appendix, which provides tabulated data and numbers for all the figures included in the report.

Chapter 18 is an appendix, which provides the list of companies and organizations mentioned in the report.

Table of Contents

1. PREFACE
1.1. Scope of the Report
1.1. Research Methodology
1.2. Chapter Outlines
 
2. EXECUTIVE SUMMARY
 
3. INTRODUCTION
3.1. Medication Non-Adherence: A National Epidemic
3.2. Medication Adherence and its Measurement
3.3. Types of Medication Non-Adherence
3.3.1. Factors Contributing to Non-Adherence
3.3.2. Impact of Non-Adherence on Health of Patients and Healthcare Industry
3.4. Improving Medication Adherence
3.4.1. Traditional Interventions
3.4.2. Modern Interventions
3.4.2.1. Connected Devices
3.4.2.2. Mobile Applications
3.4.2.3. Gamification
3.4.2.4. Compliance Packaging
3.5. Key Initiatives to Improve Medication Adherence  
4. SMART DRUG DELIVERY DEVICES: CURRENT MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Smart Drug Delivery Devices: Overall Market Landscape
4.2.1. Distribution by Year of Establishment of Developers
4.2.2. Distribution by Geographical Location of Developers
4.2.3. Distribution by Size of Developers
4.2.4. Distribution by Type of Devices
4.2.5. Distribution by Mode of Drug Delivery
4.2.6. Distribution by Key Device Specifications
4.2.6.1. Audio / Visual Reminders
4.2.6.2. Connectivity (USB, Bluetooth, or Cellular)
4.2.6.3. Companion Mobile Application
4.2.6.4. Companion Web Portal
4.2.6.5. Data Storage / Cloud Platform
4.2.6.6. Rechargeable Battery / Battery Backup
4.2.7. Key Players
4.2.8. Smart Inhalers
4.2.8.1. Distribution by Year of Establishment of Developers
4.2.8.2. Distribution by Geographical Location of Developers
4.2.8.3. Distribution by Size of Developers
4.2.8.4. Distribution by Key Device Specifications
4.2.9. Smart Injectors
4.2.9.1. Distribution by Year of Establishment of Developers
4.2.9.2. Distribution by Geographical Location of Developers
4.2.9.3. Distribution by Size of Developers
4.2.9.4. Distribution by Key Device Specifications
4.2.10. Smart Wearable Injectors
4.2.10.1. Distribution by Year of Establishment of Developers
4.2.10.2. Distribution by Geographical Location of Developers
4.2.10.3. Distribution by Size of Developers
4.2.10.4. Distribution by Key Device Specifications
4.2.11. Smart Pills / Other Smart Devices
4.2.11.1. Distribution by Year of Establishment of Developers
4.2.11.2. Distribution by Geographical Location of Developers
4.2.11.3. Distribution by Size of Developers
4.2.11.4. Distribution by Key Device Specifications
 

5. SMART ACCESSORY DEVICES AND PACKAGING SYSTEMS: CURRENT MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Smart Accessory Devices: Overall Market Landscape
5.2.1. Distribution by Year of Establishment of Developers
5.2.2. Distribution by Geographical Location of Developers
5.2.3. Distribution by Size of Developer
5.2.4. Distribution by Type of Devices
5.2.5. Distribution by Key Device Specifications
5.2.5.1. Audio / Visual Reminders
5.2.5.2. Connectivity (USB, Bluetooth, Wi-Fi, or Cellular)
5.2.5.3. Companion Mobile Application
5.2.5.4. Companion Web Portal
5.2.5.5. Data Storage / Cloud Platform
5.2.5.6. Rechargeable Battery / Battery Backup
5.2.6. Key Players
5.2.7. Smart Medication Dispensers
5.2.7.1. Distribution by Year of Establishment of Developers
5.2.7.2. Distribution by Geographical Location of Developers
5.2.7.3. Distribution by Size of Developers
5.2.7.4. Distribution by Key Device Specifications
5.2.8. Smart Pill Bottles / Caps
5.2.8.1. Distribution by Year of Establishment of Developers
5.2.8.2. Distribution by Geographical Location of Developers
5.2.8.3. Distribution by Size of Developers
5.2.8.4. Distribution by Key Device Specifications
5.2.9. Smart Pill Boxes
5.2.9.1. Distribution by Year of Establishment of Developers
5.2.9.2. Distribution by Geographical Location of Developers
5.2.9.3. Distribution by Size of Developers
5.2.9.4. Distribution by Key Device Specifications
5.2.10. Smart Blister Packs
5.2.10.1. Distribution by Year of Establishment of Developers
5.2.10.2. Distribution by Geographical Location of Developers
5.2.10.3. Distribution by Size of Developers
5.2.10.4. Distribution by Key Device Specifications
5.2.11. Other Smart Devices
5.2.11.1. Distribution by Year of Establishment of Developers
5.2.11.2. Distribution by Geographical Location of Developers
5.2.11.3. Distribution by Size of Developers
5.2.11.4. Distribution by Key Device Specifications
5.3. Compliance Packaging Systems: Overall Market Landscape
5.3.1. Distribution by Geographical Location of Developers
5.3.2. Distribution by Size of Developers
5.3.3. Distribution by Type of Packaging System
5.3.4. Distribution by Key Specifications
5.3.4.1. Distribution by Number of Doses per Pack
5.3.4.2. Distribution by Availability of Other Key Features
 

6. REGULATORY LANDSCAPE FOR CONNECTED DRUG DELIVERY SYSTEMS
6.1. Chapter Overview
6.2. North America
6.2.1. Regulatory Approval of Combination Products in the US
6.2.1.1. Overview
6.2.1.2. Historical Background
6.2.1.3. Regulatory Bodies and their Role in Product Approval
6.2.2. Regulatory Approval of Combination Products in Canada
6.2.2.1. Overview
6.2.2.2. Regulatory Bodies and Their Role in Product Approval
6.3. Europe
6.3.1. Regulatory Approval of Combination Products in Europe
6.3.1.1. Overview
6.3.1.2. Regulatory Bodies and Their Role in Product Approval
6.4. Latin America
6.4.1. Regulatory Approval of Combination Products in Brazil
6.4.1.1. Overview
6.4.1.2. Regulatory Bodies and Their Role in Product Approval
6.4.2. Regulatory Approval of Combination Products in Mexico
6.4.2.1. Overview
6.4.2.2. Regulatory Bodies and Their Role in Product Approval
6.4.3. Regulations of Combination Products in Argentina
6.4.3.1. Overview
6.4.3.2. Regulatory Bodies and Their Role in Product Approval
6.5. Asia-Pacific
6.5.1. Regulatory Approval of Combination Products in Japan
6.5.1.1. Overview
6.5.1.2. Regulatory Bodies and Their Role in Product Approval
6.5.2. Regulation of Combination Products in South Korea
6.5.2.1. Overview
6.5.2.2. Regulatory Bodies and Their Role in Product Approval
6.5.3. Regulatory Approval of Combination Products in Australia
6.5.3.1. Overview
6.5.3.2. Regulatory Bodies and Their Role in Product Approval
6.5.4. Regulatory Approval of Combination Products in China
6.5.4.1. Overview
6.5.4.2. Regulatory Bodies and Their Role in Product Approval
6.5.5. Regulations of Combination Products in India
6.5.5.1. Overview
6.5.5.2. Regulatory Bodies and Their Role in Product Approval
6.6. Middle East
6.6.1. Regulation of Combination Products in Saudi Arabia
6.6.1.1. Overview
6.6.1.2. Regulatory Bodies and Their Role in Product Approval
6.6.2. Regulation of Combination Products in United Arab Emirates
6.6.2.1. Overview
6.6.2.2. Regulatory Bodies and Their Role in Product Approval
6.7. Connected Devices: Demonstrating Safety, Effectiveness and Performance
6.8. Connected Devices: Ensuring Security of Data Captured
 

7. DRUG DELIVERY DEVICES: COMPANY PROFILES
7.1. Chapter Overview
7.2. Adherium
7.2.1. Company Overview
7.2.2. Financial Information
7.2.3. Product Portfolio
7.2.4. Research Studies and Scientific Evidence
7.2.5. Recent Developments and Future Outlook
7.3. BIOCORP
7.3.1. Company Overview
7.3.2. Financial Information
7.3.3. Product Portfolio
7.3.4. Recent Developments and Future Outlook
7.4. nGageIT Digital Health
7.4.1. Company Overview
7.4.2. Product Portfolio
7.4.3. Recent Developments and Future Outlook
7.5. Proteus Digital Health
7.5.1. Company Overview
7.5.2. Product Portfolio
7.5.3. Research Studies and Scientific Evidence
7.5.4. Recent Developments and Future Outlook
7.6. SOOIL Development
7.6.1. Company Overview
7.6.2. Product Portfolio
7.6.3. Recent Developments and Future Outlook
7.7. Ypsomed
7.7.1. Company Overview
7.7.2. Financial Information
7.7.3. Product Portfolio
7.7.4. Recent Developments and Future Outlook
 

8. ACCESSORY DEVICES: COMPANY PROFILES
8.1. Chapter Overview
8.2. AARDEX Group
8.2.1. Company Overview
8.2.2. Product Portfolio
8.2.3. Recent Developments and Future Outlook
8.3. Information Mediary
8.3.1. Company Overview
8.3.2. Product Portfolio
8.3.3. Recent Developments and Future Outlook
8.4. MedMinder Systems
8.4.1. Company Overview
8.4.2. Product Portfolio
8.4.3. Recent Developments and Future Outlook
8.5. Philips
8.5.1. Company Overview
8.5.2. Financial Information
8.5.3. Product Portfolio
8.5.4. Research Studies and Scientific Evidence
8.5.5. Recent Developments and Future Outlook
8.6. Tinylogics
8.6.1. Company Overview
8.6.2. Product Portfolio
8.6.3. Recent Developments and Future Outlook
8.7. Vaica
8.7.1. Company Overview
8.7.2. Product Portfolio
8.7.3. Research Studies and Scientific Evidence
8.7.4. Recent Developments and Future Outlook
 

9. CASE STUDIES
9.1. Chapter Overview
9.2. Case Study I: Diabetes
9.2.1. Disease Description
9.2.2. Disease Statistics
9.2.3. Economic Burden due to Non-Adherence
9.2.4. Evolution of Drug Delivery / Connected Devices for Improving Adherence
9.3. Case Study II: Asthma
9.3.1. Disease Overview
9.3.2. Disease Statistics
9.3.3. Economic Burden due to Non-Adherence
9.3.4. Evolution of Drug Delivery / Connected Devices for Improving Adherence
9.4. Case Study III: Rheumatoid Arthritis
9.4.1. Disease Overview
9.4.2. Disease Statistics
9.4.3. Economic Burden due to Non-Adherence
9.4.4. Evolution of Drug Delivery / Connected Devices for Improving Adherence
 

10. PRODUCT COMPETITIVENESS ANALYSIS
10.1. Chapter Overview
10.2. Methodology
10.2.1. Key Parameters and Methodology
10.3. Overall Product Competitiveness Analysis
10.3.1. Product Competitiveness Analysis for Smart Medication Dispensers
10.3.2. Product Competitiveness Analysis for Smart Pill Packaging Systems
10.3.3. Product Competitiveness Analysis for Smart Inhalers
10.3.4. Product Competitiveness Analysis for Smart Injectors
10.3.5. Product Competitiveness Analysis for Smart Wearable Injectors
 

11. FUNDING AND INVESTMENT ANALYSIS
11.1. Chapter Overview
11.2. Types of Funding
11.3. Drug Adherence Enhancement Market: Funding and Investment Analysis
11.3.1. Analysis by Number of Instances
11.3.2. Analysis by Amount Invested
11.3.3. Analysis by Type of Funding
11.3.4. Analysis by Number of Funding Instances and Amount Invested in Different Types of Devices
11.3.5. Most Active Players
11.3.6. Most Active Investors
11.4. Concluding Remarks
 

12. PARTNERSHIPS AND COLLABORATIONS
12.1. Chapter Overview
12.2. Partnership Models
12.3. Drug Adherence Enhancement Market: List of Partnerships and Collaborations
12.3.1. Analysis by Year of Partnership
12.3.2. Analysis by Type of Partnership
12.3.3. Analysis by Geographical Activity
12.3.4. Most Active Players: Analysis by Number of Partnerships
12.3.5. Concluding Remarks
 

13. MEDICATION ADHERENCE WITH MOBILE APPLICATIONS
13.1. Chapter Overview
13.2. The Increasing Trend of Mobile Applications in Healthcare Industry
13.3. USFDA Regulations for Mobile Medical Applications
13.4. List of Mobile Applications for Improving Medication Adherence
13.5. Medication Adherence with Mobile Applications: Clinical Research Evidence
13.5.1. Distribution by Therapeutic Area
 

14. MARKET FORECAST
14.1. Chapter Overview
14.2. Forecast Methodology and Key Assumptions
14.3. Global Drug Adherence Enhancement Market
14.3.1. Global Drug Adherence Enhancement Market, 2018-2030 (By Value)
14.3.1.1. Drug Adherence Enhancement Market for Smart Drug Delivery Devices, 2018-2030 (By Value)
14.3.1.2. Drug Adherence Enhancement Market for Smart Accessory Devices, 2018-2030 (By Value)
14.3.1.3. Drug Adherence Enhancement Market for Other Type of Devices, 2018-2030 (By Value)
14.3.2. Global Drug Adherence Enhancement Market, 2018-2030 (By Volume)
14.3.2.1. Drug Adherence Enhancement Market for Smart Drug Delivery Devices, 2018-2030 (By Volume)
14.3.2.2. Drug Adherence Enhancement Market for Smart Accessory Devices, 2018-2030 (By Volume)
14.3.2.3. Drug Adherence Enhancement Market for Other Type of Devices, 2018-2030 (By Volume)
14.4. Global Drug Adherence Enhancement Market: Distribution by Geography, 2018-2030 (By Value)
14.4.1. Drug Adherence Enhancement Market in North America, 2018-2030 (By Value)
14.4.2. Drug Adherence Enhancement Market in Europe, 2018-2030 (By Value)
14.4.3. Drug Adherence Enhancement Market in Asia-Pacific, 2018-2030 (By Value)
14.4.4. Drug Adherence Enhancement Market in Rest of the World, 2018-2030 (By Value)
14.5. Global Drug Adherence Enhancement Market: Distribution by Type of Product and Geography (By Value)
14.5.1. Drug Adherence Enhancement Market for Smart Inhalers, 2018-2030 (By Value)
14.5.1.1. Drug Adherence Enhancement Market for Smart Inhalers in North America, 2018-2030 (By Value)
14.5.1.2. Drug Adherence Enhancement Market for Smart Inhalers in Europe, 2018-2030 (By Value)
14.5.1.3. Drug Adherence Enhancement Market for Smart Inhalers in Asia-Pacific, 2018-2030 (By Value)
14.5.1.4. Drug Adherence Enhancement Market for Smart Inhalers in Rest of the World, 2018-2030 (By Value)
14.5.2. Drug Adherence Enhancement Market for Smart Injectors, 2018-2030 (By Value)
14.5.2.1. Drug Adherence Enhancement Market for Smart Injectors in North America, 2018-2030 (By Value)
14.5.2.2. Drug Adherence Enhancement Market for Smart Injectors in Europe, 2018-2030 (By Value)
14.5.2.3. Drug Adherence Enhancement Market for Smart Injectors in Asia-Pacific, 2018-2030 (By Value)
14.5.2.4. Drug Adherence Enhancement Market for Smart Injectors in Rest of the World, 2018-2030 (By Value)
14.5.3. Drug Adherence Enhancement Market for Smart Wearable Injectors, 2018-2030 (By Value)
14.5.3.1. Drug Adherence Enhancement Market for Smart Wearable Injectors in North America, 2018-2030 (By Value)
14.5.3.2. Drug Adherence Enhancement Market for Smart Wearable Injectors in Europe, 2018-2030 (By Value)
14.5.3.3. Drug Adherence Enhancement Market for Smart Wearable Injectors in Asia-Pacific, 2018-2030 (By Value)
14.5.3.4. Drug Adherence Enhancement Market for Smart Wearable Injectors in Rest of the World, 2018-2030 (By Value)
14.5.4. Drug Adherence Enhancement Market for Smart Pills, 2018-2030 (By Value)
14.5.4.1. Drug Adherence Enhancement Market for Smart Pills in North America, 2018-2030 (By Value)
14.5.4.2. Drug Adherence Enhancement Market for Smart Pills in Europe, 2018-2030 (By Value)
14.5.4.3. Drug Adherence Enhancement Market for Smart Pills in Asia-Pacific, 2018-2030 (By Value)
14.5.4.4. Drug Adherence Enhancement Market for Smart Pills in Rest of the World, 2018-2030 (By Value)
14.5.5. Drug Adherence Enhancement Market for Smart Medication Dispensers, 2018-2030 (By Value)
14.5.5.1. Drug Adherence Enhancement Market for Smart Medication Dispensers in North America, 2018-2030 (By Value)
14.5.5.2. Drug Adherence Enhancement Market for Smart Medication Dispensers in Europe, 2018-2030 (By Value)
14.5.5.3. Drug Adherence Enhancement Market for Smart Medication Dispensers in Asia-Pacific, 2018-2030 (By Value)
14.5.5.4. Drug Adherence Enhancement Market for Smart Medication Dispensers in Rest of the World, 2018-2030 (By Value)
14.5.6. Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes, 2018-2030 (By Value)
14.5.6.1. Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in North America, 2018-2030 (By Value)
14.5.6.2. Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Europe, 2018-2030 (By Value)
14.5.6.3. Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Asia-Pacific, 2018-2030 (By Value)
14.5.6.4. Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Rest of the World, 2018-2030 (By Value)
14.5.7. Drug Adherence Enhancement Market for Smart Blister Packs, 2018-2030 (By Value)
14.5.7.1. Drug Adherence Enhancement Market for Smart Blister Packs in North America, 2018-2030 (By Value)
14.5.7.2. Drug Adherence Enhancement Market for Smart Blister Packs in Europe, 2018-2030 (By Value)
14.5.7.3. Drug Adherence Enhancement Market for Smart Blister Packs in Asia-Pacific, 2018-2030 (By Value)
14.5.7.4. Drug Adherence Enhancement Market for Smart Blister Packs in Rest of the World, 2018-2030 (By Value)
14.5.8. Drug Adherence Enhancement Market for Other Type of Products, 2018-2030 (By Value)
14.5.8.1. Drug Adherence Enhancement Market for Other Type of Products in North America, 2018-2030 (By Value)
14.5.8.2. Drug Adherence Enhancement Market for Other Type of Products in Europe, 2018-2030 (By Value)
14.5.8.3. Drug Adherence Enhancement Market for Other Type of Products in Asia-Pacific, 2018-2030 (By Value)
14.5.8.4. Drug Adherence Enhancement Market for Other Type of Products in Rest of the World, 2018-2030 (By Value)
14.6. Global Drug Adherence Enhancement Market: Distribution by Type of Product (By Volume)
14.6.1. Drug Adherence Enhancement Market for Smart Inhalers, 2018-2030 (By Volume)
14.6.1.1. Drug Adherence Enhancement Market for Smart Inhalers in North America, 2018-2030 (By Volume)
14.6.1.2. Drug Adherence Enhancement Market for Smart Inhalers in Europe, 2018-2030 (By Volume)
14.6.1.3. Drug Adherence Enhancement Market for Smart Inhalers in Asia-Pacific, 2018-2030 (By Volume)
14.6.1.4. Drug Adherence Enhancement Market for Smart Inhalers in Rest of the World, 2018-2030 (By Volume)
14.6.2. Drug Adherence Enhancement Market for Smart Injectors, 2018-2030 (By Volume)
14.6.2.1. Drug Adherence Enhancement Market for Smart Injectors in North America, 2018-2030 (By Volume)
14.6.2.2. Drug Adherence Enhancement Market for Smart Injectors in Europe, 2018-2030 (By Volume)
14.6.2.3. Drug Adherence Enhancement Market for Smart Injectors in Asia-Pacific, 2018-2030 (By Volume)
14.6.2.4. Drug Adherence Enhancement Market for Smart Injectors in Rest of the World, 2018-2030 (By Volume)
14.6.3. Drug Adherence Enhancement Market for Smart Wearable Injectors, 2018-2030 (By Volume)
14.6.3.1. Drug Adherence Enhancement Market for Smart Wearable Injectors in North America, 2018-2030 (By Volume)
14.6.3.2. Drug Adherence Enhancement Market for Smart Wearable Injectors in Europe, 2018-2030 (By Volume)
14.6.3.3. Drug Adherence Enhancement Market for Smart Wearable Injectors in Asia-Pacific, 2018-2030 (By Volume)
14.6.3.4. Drug Adherence Enhancement Market for Smart Wearable Injectors in Rest of the World, 2018-2030 (By Volume)
14.6.4. Drug Adherence Enhancement Market for Smart Pills, 2018-2030 (By Volume)
14.6.4.1. Drug Adherence Enhancement Market for Smart Pills in North America, 2018-2030 (By Volume)
14.6.4.2. Drug Adherence Enhancement Market for Smart Pills in Europe, 2018-2030 (By Volume)
14.6.4.3. Drug Adherence Enhancement Market for Smart Pills in Asia-Pacific, 2018-2030 (By Volume)
14.6.4.4. Drug Adherence Enhancement Market for Smart Pills in Rest of the World, 2018-2030 (By Volume)
14.6.5. Drug Adherence Enhancement Market for Smart Medication Dispensers, 2018-2030 (By Volume)
14.6.5.1. Drug Adherence Enhancement Market for Smart Medication Dispensers in North America, 2018-2030 (By Volume)
14.6.5.2. Drug Adherence Enhancement Market for Smart Medication Dispensers in Europe, 2018-2030 (By Volume)
14.6.5.3. Drug Adherence Enhancement Market for Smart Medication Dispensers in Asia-Pacific, 2018-2030 (By Volume)
14.6.5.4. Drug Adherence Enhancement Market for Smart Medication Dispensers in Rest of the World, 2018-2030 (By Volume)
14.6.6. Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes, 2018-2030 (By Volume)
14.6.6.1. Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in North America, 2018-2030 (By Volume)
14.6.6.2. Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Europe, 2018-2030 (By Volume)
14.6.6.3. Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Asia-Pacific, 2018-2030 (By Volume)
14.6.6.4. Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Rest of the World, 2018-2030 (By Volume)
14.6.7. Drug Adherence Enhancement Market for Smart Blister Packs, 2018-2030 (By Volume)
14.6.7.1. Drug Adherence Enhancement Market for Smart Blister Packs in North America, 2018-2030 (By Volume)
14.6.7.2. Drug Adherence Enhancement Market for Smart Blister Packs in Europe, 2018-2030 (By Volume)
14.6.7.3. Drug Adherence Enhancement Market for Smart Blister Packs in Asia-Pacific, 2018-2030 (By Volume)
14.6.7.4. Drug Adherence Enhancement Market for Smart Blister Packs in Rest of the World, 2018-2030 (By Volume)
14.6.8. Drug Adherence Enhancement Market for Other Type of Products, 2018-2030 (By Volume)
14.6.8.1. Drug Adherence Enhancement Market for Other Type of Products in North America, 2018-2030 (By Volume)
14.6.8.2. Drug Adherence Enhancement Market for Other Type of Products in Europe, 2018-2030 (By Volume)
14.6.8.3. Drug Adherence Enhancement Market for Other Type of Products in Asia-Pacific, 2018-2030 (By Volume)
14.6.8.4. Drug Adherence Enhancement Market for Other Type of Products in Rest of the World, 2018-2030 (By Volume)
14.7. Global Drug Adherence Enhancement Market: Distribution by Therapeutic Area and Geography (By Value)
14.7.1. Drug Adherence Enhancement Market for Metabolic Disorders (By Value)
14.7.1.1. Drug Adherence Enhancement Market for Metabolic Disorders in North America, 2018-2030 (By Value)
14.7.1.2. Drug Adherence Enhancement Market for Metabolic Disorders in Europe, 2018-2030 (By Value)
14.7.1.3. Drug Adherence Enhancement Market for Metabolic Disorders in Asia-Pacific, 2018-2030 (By Value)
14.7.1.4. Drug Adherence Enhancement Market for Metabolic Disorders in Rest of the World, 2018-2030 (By Value)
14.7.2. Drug Adherence Enhancement Market for Cardiovascular Disorders (By Value)
14.7.2.1. Drug Adherence Enhancement Market for Cardiovascular Disorders in North America, 2018-2030 (By Value)
14.7.2.2. Drug Adherence Enhancement Market for Cardiovascular Disorders in Europe, 2018-2030 (By Value)
14.7.2.3. Drug Adherence Enhancement Market for Cardiovascular Disorders in Asia-Pacific, 2018-2030 (By Value)
14.7.2.4. Drug Adherence Enhancement Market for Cardiovascular Disorders in Rest of the World, 2018-2030 (By Value)
14.7.3. Drug Adherence Enhancement Market for Respiratory Disorders (By Value)
14.7.3.1. Drug Adherence Enhancement Market for Respiratory Disorders in North America, 2018-2030 (By Value)
14.7.3.2. Drug Adherence Enhancement Market for Respiratory Disorders in Europe, 2018-2030 (By Value)
14.7.3.3. Drug Adherence Enhancement Market for Respiratory Disorders in Asia-Pacific, 2018-2030 (By Value)
14.7.3.4. Drug Adherence Enhancement Market for Respiratory Disorders in Rest of The World, 2018-2030 (By Value)
14.7.4. Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders (By Value)
14.7.4.1. Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in North America, 2018-2030 (By Value)
14.7.4.2. Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Europe, 2018-2030 (By Value)
14.7.4.3. Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Asia-Pacific, 2018-2030 (By Value)
14.7.4.4. Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Rest of the World, 2018-2030 (By Value)
14.7.5. Drug Adherence Enhancement Market for Other Disorders (By Value)
14.7.5.1. Drug Adherence Enhancement Market for Other Disorders in North America, 2018-2030 (By Value)
14.7.5.2. Drug Adherence Enhancement Market for Other Disorders in Europe, 2018-2030 (By Value)
14.7.5.3. Drug Adherence Enhancement Market for Other Disorders in Asia-Pacific, 2018-2030 (By Value)
14.7.5.4. Drug Adherence Enhancement Market for Other Disorders in Rest of the World, 2018-2030 (By Value)
14.8. Global Drug Adherence Enhancement Market: Distribution by Therapeutic Area and Geography (By Volume)
14.8.1. Drug Adherence Enhancement Market for Metabolic Disorders (By Volume)
14.8.1.1. Drug Adherence Enhancement Market for Metabolic Disorders in North America, 2018-2030 (By Volume)
14.8.1.2. Drug Adherence Enhancement Market for Metabolic Disorders in Europe, 2018-2030 (By Volume)
14.8.1.3. Drug Adherence Enhancement Market for Metabolic Disorders in Asia-Pacific, 2018-2030 (By Volume)
14.8.1.4. Drug Adherence Enhancement Market for Metabolic Disorders in Rest of the World, 2018-2030 (By Volume)
14.8.2. Drug Adherence Enhancement Market for Cardiovascular Disorders (By Volume)
14.8.2.1. Drug Adherence Enhancement Market for Cardiovascular Disorders in North America, 2018-2030 (By Volume)
14.8.2.2. Drug Adherence Enhancement Market for Cardiovascular Disorders in Europe, 2018-2030 (By Volume)
14.8.2.3. Drug Adherence Enhancement Market for Cardiovascular Disorders in Asia-Pacific, 2018-2030 (By Volume)
14.8.2.4. Drug Adherence Enhancement Market for Cardiovascular Disorders in Rest of the World, 2018-2030 (By Volume)
14.8.3. Drug Adherence Enhancement Market for Respiratory Disorders (By Volume)
14.8.3.1. Drug Adherence Enhancement Market for Respiratory Disorders in North America, 2018-2030 (By Volume)
14.8.3.2. Drug Adherence Enhancement Market for Respiratory Disorders in Europe, 2018-2030 (By Volume)
14.8.3.3. Drug Adherence Enhancement Market for Respiratory Disorders in Asia-Pacific, 2018-2030 (By Volume)
14.8.3.4. Drug Adherence Enhancement Market for Respiratory Disorders in Rest of The World, 2018-2030 (By Volume)
14.8.4. Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders (By Volume)
14.8.4.1. Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in North America, 2018-2030 (By Volume)
14.8.4.2. Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Europe, 2018-2030 (By Volume)
14.8.4.3. Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Asia-Pacific, 2018-2030 (By Volume)
14.8.4.4. Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Rest of the World, 2018-2030 (By Volume)
14.8.5. Drug Adherence Enhancement Market for Other Disorders (By Volume)
14.8.5.1. Drug Adherence Enhancement Market for Other Disorders in North America, 2018-2030 (By Volume)
14.8.5.2. Drug Adherence Enhancement Market for Other Disorders in Europe, 2018-2030 (By Volume)
14.8.5.3. Drug Adherence Enhancement Market for Other Disorders in Asia-Pacific, 2018-2030 (By Volume)
14.8.5.4. Drug Adherence Enhancement Market for Other Disorders in Rest of the World, 2018-2030 (By Volume)
14.9. Global Drug Adherence Enhancement Market: Distribution by Route of Drug Administration and Geography (By Value)
14.9.1. Drug Adherence Enhancement Market for Products Intended for Oral Medications, 2018-2030 (By Value)
14.9.1.1. Drug Adherence Enhancement Market for Products Intended for Oral Medications in North America, 2018-2030 (By Value)
14.9.1.2. Drug Adherence Enhancement Market for Products Intended for Oral Medications in Europe, 2018-2030 (By Value)
14.9.1.3. Drug Adherence Enhancement Market for Products Intended for Oral Medications in Asia-Pacific, 2018-2030 (By Value)
14.9.1.4. Drug Adherence Enhancement Market for Products Intended for Oral Medications in Rest of the World, 2018-2030 (By Value)
14.9.2. Drug Adherence Enhancement Market for Products Intended for Injectables, 2018-2030 (By Value)
14.9.2.1. Drug Adherence Enhancement Market for Products Intended for Injectables in North America, 2018-2030 (By Value)
14.9.2.2. Drug Adherence Enhancement Market for Products Intended for Injectables in Europe, 2018-2030 (By Value)
14.9.2.3. Drug Adherence Enhancement Market for Products Intended for Injectables in Asia-Pacific, 2018-2030 (By Value)
14.9.2.4. Drug Adherence Enhancement Market for Products Intended for Injectables in Rest of the World, 2018-2030 (By Value)
14.9.3. Drug Adherence Enhancement Market for Products Intended for Inhalable Medications, 2018-2030 (By Value)
14.9.3.1. Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in North America, 2018-2030 (By Value)
14.9.3.2. Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Europe, 2018-2030 (By Value)
14.9.3.3. Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Asia-Pacific, 2018-2030 (By Value)
14.9.3.4. Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Rest of the World, 2018-2030 (By Value)
14.9.4. Drug Adherence Enhancement Market for Products Intended for Other Medications, 2018-2030 (By Value)
14.9.4.1. Drug Adherence Enhancement Market for Products Intended for Other Medications in North America, 2018-2030 (By Value)
14.9.4.2. Drug Adherence Enhancement Market for Products Intended for Other Medications in Europe, 2018-2030 (By Value)
14.9.4.3. Drug Adherence Enhancement Market for Products Intended for Other Medications in Asia-Pacific, 2018-2030 (By Value)
14.9.4.4. Drug Adherence Enhancement Market for Products Intended for Other Medications in Rest of the World, 2018-2030 (By Value)
14.10. Global Drug Adherence Enhancement Market: Distribution by Route of Drug Administration and Geography (By Volume)
14.10.1. Drug Adherence Enhancement Market for Products Intended for Oral Medications, 2018-2030 (By Volume)
14.10.1.1. Drug Adherence Enhancement Market for Products Intended for Oral Medications in North America, 2018-2030 (By Volume)
14.10.1.2. Drug Adherence Enhancement Market for Products Intended for Oral Medications in Europe, 2018-2030 (By Volume)
14.10.1.3. Drug Adherence Enhancement Market for Products Intended for Oral Medications in Asia-Pacific, 2018-2030 (By Volume)
14.10.1.4. Drug Adherence Enhancement Market for Products Intended for Oral Medications in Rest of the World, 2018-2030 (By Volume)
14.10.2. Drug Adherence Enhancement Market for Products Intended for Injectables, 2018-2030 (By Volume)
14.10.2.1. Drug Adherence Enhancement Market for Products Intended for Injectables in North America, 2018-2030 (By Volume)
14.10.2.2. Drug Adherence Enhancement Market for Products Intended for Injectables in Europe, 2018-2030 (By Volume)
14.10.2.3. Drug Adherence Enhancement Market for Products Intended for Injectables in Asia-Pacific, 2018-2030 (By Volume)
14.10.2.4. Drug Adherence Enhancement Market for Products Intended for Injectables in Rest of the World, 2018-2030 (By Volume)
14.10.3. Drug Adherence Enhancement Market for Products Intended for Inhalable Medications, 2018-2030 (By Volume)
14.10.3.1. Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in North America, 2018-2030 (By Volume)
14.10.3.2. Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Europe, 2018-2030 (By Volume)
14.10.3.3. Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Asia-Pacific, 2018-2030 (By Volume)
14.10.3.4. Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Rest of the World, 2018-2030 (By Volume)
14.10.4. Drug Adherence Enhancement Market for Products Intended for Other Medications, 2018-2030 (By Volume)
14.10.4.1. Drug Adherence Enhancement Market for Products Intended for Other Medications in North America, 2018-2030 (By Volume)
14.10.4.2. Drug Adherence Enhancement Market for Products Intended for Other Medications in Europe, 2018-2030 (By Volume)
14.10.4.3. Drug Adherence Enhancement Market for Products Intended for Other Medications in Asia-Pacific, 2018-2030 (By Volume)
14.10.4.4. Drug Adherence Enhancement Market for Products Intended for Other Medications in Rest of the World, 2018-2030 (By Volume)
 

15. CONCLUSION
15.1. Poor Adherence to Therapies for the Treatment of Chronic Disorders Poses a Significant Economic Burden on the Healthcare Industry
15.2. Presently, Several Players are Developing IoT-Enabled / Connected Devices for Improving Medication Adherence; Majority of these are Small-sized Companies based in the US
15.3. Increasing Financial Support from Various Investors is Indicative of Future Opportunities related to Novel Strategies for Medication Adherence Improvement
15.4. Players have Entered into Strategic Collaborations to Support the Development of their Smart Products
15.5. Availability of Standalone, as well as Companion Mobile Applications, is Expected to Provide a More Integrated Approach for Improving Adherence
15.6. With Increasing Focus on Improving Therapy Efficacy and Alleviating Healthcare Burden, the Overall Market is Anticipated to Witness Steady Growth
 

16. EXECUTIVE INSIGHTS
16.1. Chapter Overview
16.2. AARDEX Group
16.2.1. Company Snapshot
16.2.2. Interview Transcript: Bernard Vrijens, Chief Executive Officer
16.3. AceAge
16.3.1. Company Snapshot
16.3.2. Interview Transcript: Spencer Waugh, Chief Executive Officer
16.4. AdhereTech
16.4.1. Company Snapshot
16.4.2. Interview Transcript: Josh Stein, Chief Executive Officer
16.5. Amiko Digital Health
16.5.1. Company Snapshot
16.5.2. Interview Transcript: Duilio Macchi, Chief Executive Officer
16.6. Cognita Labs
16.6.1. Company Snapshot
16.6.2. Interview Transcript: Gaurav Patel, Chief Technical Officer
16.7. etectRx
16.7.1. Company Snapshot
16.7.2. Interview Transcript: Tina Valbh, Strategy and Business Development (Advisor)
16.8. PharmAdva
16.8.1. Company Snapshot
16.8.2. Interview Transcript: Jonathan Sacks, Chief Executive Officer and Chairman
16.9. Popit Technologies
16.9.1. Company Snapshot
16.9.2. Interview Transcript: Timo Heikkil, Co-Founder and Chief Operating Officer
16.10. Wealth Taxi
16.10.1. Company Snapshot
16.10.2. Interview Transcript: Moore Greenberg, Founder
16.11 Small-sized Company
16.11.1 Interview Transcript: Anonymous
 

17. APPENDIX 1: TABULATED DATA
 

18. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Figures

Figure 3.1 Types of Medication Non-Adherence
Figure 3.2 Factors Contributing to Non-Adherence
Figure 3.3 Framework of IoT Assisted Adherence Platform
Figure 4.1 Smart Drug Delivery Devices: Distribution of Developers by Year of Establishment
Figure 4.2 Smart Drug Delivery Devices: Distribution of Developers by Geographical Location (Region-wise)
Figure 4.3 Smart Drug Delivery Devices: Distribution of Developers by Geographical Location (Country-wise)
Figure 4.4 Smart Drug Delivery Devices: Distribution of Developers by Size (Employee Count)
Figure 4.5 Smart Drug Delivery Devices: Distribution by Type of Device
Figure 4.6 Smart Drug Delivery Devices: Distribution by Mode of Drug Delivery
Figure 4.7 Smart Drug Delivery Devices: Distribution by Key Specifications
Figure 4.8 Smart Drug Delivery Devices: Distribution by Availability of Audio / Visual Reminders
Figure 4.9 Smart Drug Delivery Devices: Distribution by Availability of Connectivity (USB, Bluetooth, or Cellular)
Figure 4.10 Smart Drug Delivery Devices: Distribution by Availability of Companion Mobile Application
Figure 4.11 Smart Drug Delivery Devices: Distribution by Availability of Companion Web Portal
Figure 4.12 Smart Drug Delivery Devices: Distribution by Availability of Data Storage / Cloud Platform
Figure 4.13 Smart Drug Delivery Devices: Distribution by Battery Backup / Rechargeable Battery
Figure 4.14 Smart Drug Delivery Devices: Key Players
Figure 4.15 Smart Inhalers: Distribution of Developers by Year of Establishment
Figure 4.16 Smart Inhalers: Distribution of Developers by Geographical Location
Figure 4.17 Smart Inhalers: Distribution of Developers by Size (Employee Count)
Figure 4.18 Smart Inhalers: Distribution by Key Device Specifications
Figure 4.19 Smart Injectors: Distribution of Developers by Year of Establishment
Figure 4.20 Smart Injectors: Distribution of Developers by Geographical Location
Figure 4.21 Smart Injectors: Distribution of Developers by Size (Employee Count)
Figure 4.22 Smart Injectors: Distribution by Key Device Specifications
Figure 4.23 Smart Wearable Injectors: Distribution of Developers by Year of Establishment
Figure 4.24 Smart Wearable Injectors: Distribution of Developers by Geographical Location
Figure 4.25 Smart Wearable Injectors: Distribution of Developers by Size (Employee Count)
Figure 4.26 Smart Wearable Injectors: Distribution by Key Device Specifications
Figure 4.27 Smart Pills / Other Smart Devices: Distribution of Developers by Year of Establishment
Figure 4.28 Smart Pills / Other Smart Devices: Distribution of Developers by Geographical Location
Figure 4.29 Smart Pills / Other Smart Devices: Distribution of Developers by Size (Employee Count)
Figure 4.30 Smart Pills / Other Smart Devices: Distribution by Key Device Specifications
Figure 5.1 Smart Accessory Devices: Distribution of Developers by Year of Establishment
Figure 5.2 Smart Accessory Devices: Distribution of Developers by Geographical Location (Region-wise)
Figure 5.3 Smart Accessory Devices: Distribution of Developers by Geographical Location (Country-wise)
Figure 5.4 Smart Accessory Devices: Distribution of Developers by Size (Employee Count) 
Figure 5.5 Smart Accessory Devices: Distribution by Type of Device
Figure 5.6 Smart Accessory Devices: Distribution by Key Specifications
Figure 5.7 Smart Accessory Devices: Distribution by Availability of Audio / Visual Reminders
Figure 5.8 Smart Accessory Devices: Distribution by Availability of Connectivity (USB, Bluetooth, Wi-Fi, or Cellular)
Figure 5.9 Smart Accessory Devices: Distribution by Availability of Companion Mobile Application
Figure 5.10 Smart Accessory Devices: Distribution by Availability of Companion Web Portal
Figure 5.11 Smart Accessory Devices: Distribution by Availability of Data Storage / Cloud Platform
Figure 5.12 Smart Accessory Devices: Distribution by Availability of Battery Backup / Rechargeable
Figure 5.13 Smart Accessory Devices: Key Players
Figure 5.14 Smart Medication Dispensers: Distribution of Developers by Year of Establishment
Figure 5.15 Smart Medication Dispensers: Distribution of Developers by Geographical Location
Figure 5.16 Smart Medication Dispensers: Distribution of Developers by Size (Employee Count)
Figure 5.17 Smart Medication Dispensers: Distribution by Key Device Specifications
Figure 5.18 Smart Pill Bottles / Caps: Distribution of Developers by Year of Establishment
Figure 5.19 Smart Pill Bottles / Caps: Distribution of Developers by Geographical Location
Figure 5.20 Smart Pill Bottles / Caps: Distribution of Developers by Size (Employee Count)
Figure 5.21 Smart Pill Bottles / Caps: Distribution by Key Device Specifications
Figure 5.22 Smart Pill Boxes: Distribution of Developers by Year of Establishment
Figure 5.23 Smart Pill Boxes: Distribution of Developers by Geographical Location
Figure 5.24 Smart Pill Boxes: Distribution of Developers by Size (Employee Count)
Figure 5.25 Smart Pill Boxes: Distribution by Key Device Specifications
Figure 5.26 Smart Blister Packs: Distribution of Developers by Year of Establishment
Figure 5.27 Smart Blister Packs: Distribution of Developers by Geographical Location
Figure 5.28 Smart Blister Packs: Distribution of Developers by Size (Employee Count)
Figure 5.29 Smart Blister Packs: Distribution by Key Device Specifications
Figure 5.30 Other Smart Devices: Distribution of Developers by Year of Establishment
Figure 5.31 Other Smart Devices: Distribution of Developers by Geographical Location
Figure 5.32 Other Smart Devices: Distribution of Developers by Size (Employee Count)
Figure 5.33 Other Smart Devices: Distribution by Key Device Specifications
Figure 5.34 Compliance Packaging Systems: Distribution of Developers by Geographical Location
Figure 5.35 Compliance Packaging Systems: Distribution of Developers by Size (Employee Count)
Figure 5.36 Compliance Packaging Systems: Distribution by Type of Packaging System
Figure 5.37 Compliance Packaging Systems: Distribution by Number of Doses per Pack
Figure 5.38 Compliance Packaging Systems: Distribution by Availability of Other Features 
Figure 6.1 Global Regulations Related to Smart Inhalers, Smart Injectors and Smart Wearable Injectors
Figure 6.2 USFDA: Approval Pathway for Combination Products
Figure 6.3 Health Canada: Approval Pathway for Combination Products
Figure 6.4 CFDA: Approval Pathway of Combination Products 
Figure 7.1 Adherium: Annual Revenues, FY 2015-H1 FY 2018 (USD Million)
Figure 7.2 Adherium: Working Mechanism of Hailie™
Figure 7.3 BIOCORP: Annual Revenues, 2014-2017 (EUR Million)
Figure 7.4 nGageIT Digital Health: Data Points Captured by Nanoparticle Sensor
Figure 7.5 nGageIT Digital Health: Key Features of nGageIT Injectable Sensor Technologies
Figure 7.6 Proteus Digital Health: Major Components of Proteus Discover
Figure 7.7 Ypsomed: Annual Revenues, FY2013 – FY2017 (CHF Million)
Figure 7.8 Ypsomed: Sales by Business Divisions, FY2017 (CHF Million)
Figure 7.9. Ypsomed: Features of YpsoMate® SmartPilot
Figure 7.10. Ypsomed: Components of mylife Ypsopump
Figure 8.1 MedMinder Systems: Key Features of Pill Dispensers
Figure 8.2 MedMinder Systems: Key Differences of Pill Dispensers
Figure 8.3 Philips: Annual Revenues, 2013- H1 2018 (EUR Billion)
Figure 8.4 Philips: Revenues by Business Segments, H1 2018 (EUR Billion)
Figure 8.5 Philips: Key Features of spencer®
Figure 8.6 Tinylogics: Key Features of Memo Box
Figure 8.7 Vaica: Complete Range of Solutions
Figure 8.8 Vaica: Study Results
Figure 9.1 Diabetes: Global Prevalence
Figure 9.2 Diabetes: Evolution of Drug Delivery / Connected Devices 
Figure 9.3 Impact of Drug Delivery / Connected Devices in Improving Drug Adherence in Diabetic Patients: Highlights on Twitter
Figure 9.4 Asthma: Global Prevalence
Figure 9.5 Asthma: Evolution of Drug Delivery / Connected Devices 
Figure 9.6 Smart Inhalers / Connected Devices: Potential Applications
Figure 9.10 Impact of Drug Delivery / Connected Devices in Improving Drug Adherence in Asthma Patients: Highlights on Twitter
Figure 9.11 Rheumatoid Arthritis: Global Prevalence
Figure 9.12 Rheumatoid Arthritis: Evolution of Drug Delivery / Connected Devices 
Figure 9.13 Impact of Drug Delivery / Connected Devices in Improving Drug Adherence in Rheumatoid Arthritis Patients: Highlights on Twitter
Figure 10.1 Overall Product Competitiveness Analysis
Figure 10.2 Overall Product Competitiveness Analysis: Distribution of Different Types of Products by Scores
Figure 10.3 Product Competitiveness Analysis: Smart Medication Dispensers
Figure 10.4 Product Competitiveness Analysis: Smart Pill Packaging Systems
Figure 10.5 Product Competitiveness Analysis: Smart Inhalers
Figure 10.6 Product Competitiveness Analysis: Smart Injectors
Figure 10.7 Product Competitiveness Analysis: Smart Wearable Injectors
Figure 11.1 Funding and Investment Analysis: Cumulative Number of Instances, January 2001-August 2018
Figure 11.2 Funding and Investment Analysis: Cumulative Amount Invested, January 2001-August 2018 (USD Million)
Figure 11.3 Funding and Investment Analysis: Distribution by Type of Funding, January 2001-August 2018
Figure 11.4 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding, January 2001-August 2018 (USD Million)
Figure 11.5 Funding and Investment Analysis: Summary of Investments, January 2001-August 2018 (USD Million)
Figure 11.6 Funding and Investment Analysis: Distribution of Number of Funding Instances by Year of Investment and Major Device Categories, January 2001-August 2018
Figure 11.7 Funding and Investment Analysis: Distribution of Number of Funding Instances by Type of Funding and Major Device Categories, January 2001-August 2018
Figure 11.8 Funding and Investment Analysis: Distribution of Amount Invested by Year of Investment and Major Device Categories, January 2001-August 2018
Figure 11.9 Funding and Investment Analysis: Most Active Players in terms of Number of Instances, January 2001-August 2018
Figure 11.10 Funding and Investment Analysis: Most Active Players in terms of Amount Raised (USD Million), January 2001-August 2018
Figure 11.12 Funding and Investment Analysis: Most Active Investors
Figure 11.13 Funding and Investment Summary
Figure 12.1 Partnerships and Collaborations: Distribution by Year, 2010-2018
Figure 12.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 12.3 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Figure 12.4 Partnerships and Collaborations: Most Active Players
Figure 12.5 Partnerships and Collaborations: Distribution by Type and Year of Partnership
Figure 12.6 Partnerships and Collaborations: Distribution by Type of Partnership and Geographical Presence of Companies
Figure 12.7 Partnerships and Collaborations: Regional Distribution
Figure 13.1 Clinical Trial Publications for Improving Medication Adherence through Software Applications: Distribution by Therapeutic Areas
Figure 14.1 Global Drug Adherence Enhancement Market, 2018-2030 (USD Billion)
Figure 14.2 Drug Adherence Enhancement Market for Smart Drug Delivery Devices, 2018-2030 (USD Billion)
Figure 14.3 Drug Adherence Enhancement Market for Smart Accessory Devices, 2018-2030 (USD Billion)
Figure 14.4 Drug Adherence Enhancement Market for Other Type of Devices, 2018-2030 (USD Billion)
Figure 14.5 Global Drug Adherence Enhancement Market, 2018-2030 (Units, Million)
Figure 14.6 Drug Adherence Enhancement Market for Smart Drug Delivery Devices, 2018-2030 (Units, Million)
Figure 14.7 Drug Adherence Enhancement Market for Smart Accessory Devices, 2018-2030 (Units, Million)
Figure 14.8 Drug Adherence Enhancement Market for Other Type of Devices, 2018-2030 (Units, Million)
Figure 14.9 Drug Adherence Enhancement Market in North America, 2018-2030 (USD Billion)
Figure 14.10 Drug Adherence Enhancement Market in Europe, 2018-2030 (USD Billion)
Figure 14.11 Drug Adherence Enhancement Market in Asia-Pacific, 2018-2030 (USD Billion)
Figure 14.12 Drug Adherence Enhancement Market in Rest of the World, 2018-2030 (USD Billion)
Figure 14.13 Drug Adherence Enhancement Market for Smart Inhalers, 2018-2030 (USD Billion)
Figure 14.14 Drug Adherence Enhancement Market for Smart Inhalers in North America, 2018-2030 (USD Billion)
Figure 14.15 Drug Adherence Enhancement Market for Smart Inhalers in Europe, 2018-2030 (USD Billion)
Figure 14.16 Drug Adherence Enhancement Market for Smart Inhalers in Asia-Pacific, 2018-2030 (USD Billion)
Figure 14.17 Drug Adherence Enhancement Market for Smart Inhalers in Rest of the World, 2018-2030 (USD Billion)
Figure 14.18 Drug Adherence Enhancement Market for Smart Injectors, 2018-2030 (USD Billion)
Figure 14.19 Drug Adherence Enhancement Market for Smart Injectors in North America, 2018-2030 (USD Billion)
Figure 14.20 Drug Adherence Enhancement Market for Smart Injectors in Europe, 2018-2030 (USD Billion)
Figure 14.21 Drug Adherence Enhancement Market for Smart Injectors in Asia-Pacific, 2018-2030 (USD Billion)
Figure 14.22 Drug Adherence Enhancement Market for Smart Injectors in Rest of the World, 2018-2030 (USD Billion)
Figure 14.23 Drug Adherence Enhancement Market for Smart Wearable Injectors, 2018-2030 (USD Billion)
Figure 14.24 Drug Adherence Enhancement Market for Smart Wearable Injectors in North America, 2018-2030 (USD Billion)
Figure 14.25 Drug Adherence Enhancement Market for Smart Wearable Injectors in Europe, 2018-2030 (USD Billion)
Figure 14.26 Drug Adherence Enhancement Market for Smart Wearable Injectors in Asia-Pacific, 2018-2030 (USD Billion)
Figure 14.27 Drug Adherence Enhancement Market for Smart Wearable Injectors in Rest of the World, 2018-2030 (USD Billion)
Figure 14.28 Drug Adherence Enhancement Market for Smart Pills, 2018-2030 (USD Billion)
Figure 14.29 Drug Adherence Enhancement Market for Smart Pills in North America, 2018-2030 (USD Billion)
Figure 14.30 Drug Adherence Enhancement Market for Smart Pills in Europe, 2018-2030 (USD Billion)
Figure 14.31 Drug Adherence Enhancement Market for Smart Pills in Asia-Pacific, 2018-2030 (USD Billion)
Figure 14.32 Drug Adherence Enhancement Market for Smart Pills in Rest of the World, 2018-2030 (USD Billion)
Figure 14.33 Drug Adherence Enhancement Market for Smart Medication Dispensers, 2018-2030 (USD Billion)
Figure 14.34 Drug Adherence Enhancement Market for Smart Medication Dispensers in North America, 2018-2030 (USD Billion)
Figure 14.35 Drug Adherence Enhancement Market for Smart Medication Dispensers in Europe, 2018-2030 (USD Billion)
Figure 14.36 Drug Adherence Enhancement Market for Smart Medication Dispensers in Asia-Pacific, 2018-2030 (USD Billion)
Figure 14.37 Drug Adherence Enhancement Market for Smart Medication Dispensers in Rest of the World, 2018-2030 (USD Billion)
Figure 14.38 Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes, 2018-2030 (USD Billion)
Figure 14.39 Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in North America, 2018-2030 (USD Billion)
Figure 14.40 Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Europe, 2018-2030 (USD Billion)
Figure 14.41 Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Asia-Pacific, 2018-2030 (USD Billion)
Figure 14.42 Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Rest of the World, 2018-2030 (USD Billion)
Figure 14.43 Drug Adherence Enhancement Market for Smart Blister Packs, 2018-2030 (USD Billion)
Figure 14.44 Drug Adherence Enhancement Market for Smart Blister Packs in North America, 2018-2030 (USD Billion)
Figure 14.45 Drug Adherence Enhancement Market for Smart Blister Packs in Europe, 2018-2030 (USD Billion)
Figure 14.46 Drug Adherence Enhancement Market for Smart Blister Packs in Asia-Pacific, 2018-2030 (USD Billion)
Figure 14.47 Drug Adherence Enhancement Market for Smart Blister Packs in Rest of the World, 2018-2030 (USD Billion)
Figure 14.48 Drug Adherence Enhancement Market for Other Type of Products, 2018-2030 (USD Billion)
Figure 14.49 Drug Adherence Enhancement Market for Other Type of Products in North America, 2018-2030 (USD Billion)
Figure 14.50 Drug Adherence Enhancement Market for Other Type of Products in Europe, 2018-2030 (USD Billion)
Figure 14.51 Drug Adherence Enhancement Market for Other Type of Products in Asia-Pacific, 2018-2030 (USD Billion)
Figure 14.52 Drug Adherence Enhancement Market for Other Type of Products in Rest of the World, 2018-2030 (USD Billion)
Figure 14.53 Drug Adherence Enhancement Market for Smart Inhalers, 2018-2030 (Units, Million)
Figure 14.54 Drug Adherence Enhancement Market for Smart Inhalers in North America, 2018-2030 (Units, Million)
Figure 14.55 Drug Adherence Enhancement Market for Smart Inhalers in Europe, 2018-2030 (Units, Million)
Figure 14.56 Drug Adherence Enhancement Market for Smart Inhalers in Asia-Pacific, 2018-2030 (Units, Million)
Figure 14.57 Drug Adherence Enhancement Market for Smart Inhalers in Rest of the World, 2018-2030 (Units, Million)
Figure 14.58 Drug Adherence Enhancement Market for Smart Injectors, 2018-2030 (Units, Million)
Figure 14.59 Drug Adherence Enhancement Market for Smart Injectors in North America, 2018-2030 (Units, Million)
Figure 14.60 Drug Adherence Enhancement Market for Smart Injectors in Europe, 2018-2030 (Units, Million)
Figure 14.61 Drug Adherence Enhancement Market for Smart Injectors in Asia-Pacific, 2018-2030 (Units, Million)
Figure 14.62 Drug Adherence Enhancement Market for Smart Injectors in Rest of the World, 2018-2030 (Units, Million)
Figure 14.63 Drug Adherence Enhancement Market for Smart Wearable Injectors, 2018-2030 (Units, Million)
Figure 14.64 Drug Adherence Enhancement Market for Smart Wearable Injectors in North America, 2018-2030 (Units, Million)
Figure 14.65 Drug Adherence Enhancement Market for Smart Wearable Injectors in Europe, 2018-2030 (Units, Million)
Figure 14.66 Drug Adherence Enhancement Market for Smart Wearable Injectors in Asia-Pacific, 2018-2030 (Units, Million)
Figure 14.67 Drug Adherence Enhancement Market for Smart Wearable Injectors in Rest of the World, 2018-2030 (Units, Million)
Figure 14.68 Drug Adherence Enhancement Market for Smart Pills, 2018-2030 (Units, Million)
Figure 14.69 Drug Adherence Enhancement Market for Smart Pills in North America, 2018-2030 (Units, Million)
Figure 14.70 Drug Adherence Enhancement Market for Smart Pills in Europe, 2018-2030 (Units, Million)
Figure 14.71 Drug Adherence Enhancement Market for Smart Pills in Asia-Pacific, 2018-2030 (Units, Million)
Figure 14.72 Drug Adherence Enhancement Market for Smart Pills in Rest of the World, 2018-2030 (Units, Million)
Figure 14.73 Drug Adherence Enhancement Market for Smart Medication Dispensers, 2018-2030 (Units, Million)
Figure 14.74 Drug Adherence Enhancement Market for Smart Medication Dispensers in North America, 2018-2030 (Units, Million)
Figure 14.75 Drug Adherence Enhancement Market for Smart Medication Dispensers in Europe, 2018-2030 (Units, Million)
Figure 14.76 Drug Adherence Enhancement Market for Smart Medication Dispensers in Asia-Pacific, 2018-2030 (Units, Million)
Figure 14.77 Drug Adherence Enhancement Market for Smart Medication Dispensers in Rest of the World, 2018-2030 (Units, Million)
Figure 14.78 Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes, 2018-2030 (Units, Million)
Figure 14.79 Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in North America, 2018-2030 (Units, Million)
Figure 14.80 Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Europe, 2018-2030 (Units, Million)
Figure 14.81 Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Asia-Pacific, 2018-2030 (Units, Million)
Figure 14.82 Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Rest of the World, 2018-2030 (Units, Million)
Figure 14.83 Drug Adherence Enhancement Market for Smart Blister Packs, 2018-2030 (Units, Million)
Figure 14.84 Drug Adherence Enhancement Market for Smart Blister Packs in North America, 2018-2030 (Units, Million)
Figure 14.85 Drug Adherence Enhancement Market for Smart Blister Packs in Europe, 2018-2030 (Units, Million)
Figure 14.86 Drug Adherence Enhancement Market for Smart Blister Packs in Asia-Pacific, 2018-2030 (Units, Million)
Figure 14.87 Drug Adherence Enhancement Market for Smart Blister Packs in Rest of the World, 2018-2030 (Units, Million)
Figure 14.88 Drug Adherence Enhancement Market for Other Type of Products, 2018-2030 (Units, Million)
Figure 14.89 Drug Adherence Enhancement Market for Other Type of Products in North America, 2018-2030 (Units, Million)
Figure 14.90 Drug Adherence Enhancement Market for Other Type of Products in Europe, 2018-2030 (Units, Million)
Figure 14.91 Drug Adherence Enhancement Market for Other Type of Products in Asia-Pacific, 2018-2030 (Units, Million)
Figure 14.92 Drug Adherence Enhancement Market for Other Type of Products in Rest of the World, 2018-2030 (Units, Million)
Figure 14.93 Drug Adherence Enhancement Market for Metabolic Disorders, 2018-2030 (USD Billion)
Figure 14.94 Drug Adherence Enhancement Market for Metabolic Disorders in North America, 2018-2030 (USD Billion)
Figure 14.95 Drug Adherence Enhancement Market for Metabolic Disorders in Europe, 2018-2030 (USD Billion)
Figure 14.96 Drug Adherence Enhancement Market for Metabolic Disorders in Asia-Pacific, 2018-2030 (USD Billion)
Figure 14.97 Drug Adherence Enhancement Market for Metabolic Disorders in Rest of the World, 2018-2030 (USD Billion)
Figure 14.98 Drug Adherence Enhancement Market for Cardiovascular Disorders, 2018-2030 (USD Billion)
Figure 14.99 Drug Adherence Enhancement Market for Cardiovascular Disorders in North America, 2018-2030 (USD Billion)
Figure 14.100 Drug Adherence Enhancement Market for Cardiovascular Disorders in Europe, 2018-2030 (USD Billion)
Figure 14.101 Drug Adherence Enhancement Market for Cardiovascular Disorders in Asia-Pacific, 2018-2030 (USD Billion)
Figure 14.102 Drug Adherence Enhancement Market for Cardiovascular Disorders in Rest of the World, 2018-2030 (USD Billion)
Figure 14.103 Drug Adherence Enhancement Market for Respiratory Disorders, 2018-2030 (USD Billion)
Figure 14.104 Drug Adherence Enhancement Market for Respiratory Disorders in North America, 2018-2030 (USD Billion)
Figure 14.105 Drug Adherence Enhancement Market for Respiratory Disorders in Europe, 2018-2030 (USD Billion)
Figure 14.106 Drug Adherence Enhancement Market for Respiratory Disorders in Asia-Pacific, 2018-2030 (USD Billion)
Figure 14.107 Drug Adherence Enhancement Market for Respiratory Disorders in Rest of the World, 2018-2030 (USD Billion)
Figure 14.108 Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders, 2018-2030 (USD Billion)
Figure 14.109 Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in North America, 2018-2030 (USD Billion)
Figure 14.110 Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Europe, 2018-2030 (USD Billion)
Figure 14.111 Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Asia-Pacific, 2018-2030 (USD Billion)
Figure 14.112 Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Rest of the World, 2018-2030 (USD Billion)
Figure 14.113 Drug Adherence Enhancement Market for Other Disorders, 2018-2030 (USD Billion)
Figure 14.114 Drug Adherence Enhancement Market for Other Disorders in North America, 2018-2030 (USD Billion)
Figure 14.115 Drug Adherence Enhancement Market for Other Disorders in Europe, 2018-2030 (USD Billion)
Figure 14.116 Drug Adherence Enhancement Market for Other Disorders in Asia-Pacific, 2018-2030 (USD Billion)
Figure 14.117 Drug Adherence Enhancement Market for Other Disorders in Rest of the World, 2018-2030 (USD Billion)
Figure 14.118 Drug Adherence Enhancement Market for Metabolic Disorders, 2018-2030 (Units, Million)
Figure 14.119 Drug Adherence Enhancement Market for Metabolic Disorders in North America, 2018-2030 (Units, Million)
Figure 14.120 Drug Adherence Enhancement Market for Metabolic Disorders in Europe, 2018-2030 (Units, Million)
Figure 14.121 Drug Adherence Enhancement Market for Metabolic Disorders in Asia-Pacific, 2018-2030 (Units, Million)
Figure 14.122 Drug Adherence Enhancement Market for Metabolic Disorders in Rest of the World, 2018-2030 (Units, Million)
Figure 14.123 Drug Adherence Enhancement Market for Cardiovascular Disorders, 2018-2030 (Units, Million)
Figure 14.124 Drug Adherence Enhancement Market for Cardiovascular Disorders in North America, 2018-2030 (Units, Million)
Figure 14.125 Drug Adherence Enhancement Market for Cardiovascular Disorders in Europe, 2018-2030 (Units, Million)
Figure 14.126 Drug Adherence Enhancement Market for Cardiovascular Disorders in Asia-Pacific, 2018-2030 (Units, Million)
Figure 14.127 Drug Adherence Enhancement Market for Cardiovascular Disorders in Rest of the World, 2018-2030 (Units, Million)
Figure 14.128 Drug Adherence Enhancement Market for Respiratory Disorders, 2018-2030 (Units, Million)
Figure 14.129 Drug Adherence Enhancement Market for Respiratory Disorders in North America, 2018-2030 (Units, Million)
Figure 14.130 Drug Adherence Enhancement Market for Respiratory Disorders in Europe, 2018-2030 (Units, Million)
Figure 14.131 Drug Adherence Enhancement Market for Respiratory Disorders in Asia-Pacific, 2018-2030 (Units, Million)
Figure 14.132 Drug Adherence Enhancement Market for Respiratory Disorders in Rest of the World, 2018-2030 (Units, Million)
Figure 14.133 Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders, 2018-2030 (Units, Million)
Figure 14.134 Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in North America, 2018-2030 (Units, Million)
Figure 14.135 Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Europe, 2018-2030 (Units, Million)
Figure 14.136 Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Asia-Pacific, 2018-2030 (Units, Million)
Figure 14.137 Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Rest of the World, 2018-2030 (Units, Million)
Figure 14.138 Drug Adherence Enhancement Market for Other Disorders, 2018-2030 (Units, Million)
Figure 14.139 Drug Adherence Enhancement Market for Other Disorders in North America, 2018-2030 (Units, Million)
Figure 14.140 Drug Adherence Enhancement Market for Other Disorders in Europe, 2018-2030 (Units, Million)
Figure 14.141 Drug Adherence Enhancement Market for Other Disorders in Asia-Pacific, 2018-2030 (Units, Million)
Figure 14.142 Drug Adherence Enhancement Market for Other Disorders in Rest of the World, 2018-2030 (Units, Million)
Figure 14.143 Drug Adherence Enhancement Market for Products Intended for Oral Medications, 2018-2030 (USD Billion)
Figure 14.144 Drug Adherence Enhancement Market for Products Intended for Oral Medications in North America, 2018-2030 (USD Billion)
Figure 14.145 Drug Adherence Enhancement Market for Products Intended for Oral Medications in Europe, 2018-2030 (USD Billion)
Figure 14.146 Drug Adherence Enhancement Market for Products Intended for Oral Medications in Asia-Pacific, 2018-2030 (USD Billion)
Figure 14.147 Drug Adherence Enhancement Market for Products Intended for Oral Medications in Rest of the World, 2018-2030 (USD Billion)
Figure 14.148 Drug Adherence Enhancement Market for Products Intended for Injectables, 2018-2030 (USD Billion)
Figure 14.149 Drug Adherence Enhancement Market for Products Intended for Injectables in North America, 2018-2030 (USD Billion)
Figure 14.150 Drug Adherence Enhancement Market for Products Intended for Injectables in Europe, 2018-2030 (USD Billion)
Figure 14.151 Drug Adherence Enhancement Market for Products Intended for Injectables in Asia-Pacific, 2018-2030 (USD Billion)
Figure 14.152 Drug Adherence Enhancement Market for Products Intended for Injectables in Rest of the World, 2018-2030 (USD Billion)
Figure 14.153 Drug Adherence Enhancement Market for Products Intended for Inhalable Medications, 2018-2030 (USD Billion)
Figure 14.154 Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in North America, 2018-2030 (USD Billion)
Figure 14.155 Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Europe, 2018-2030 (USD Billion)
Figure 14.156 Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Asia-Pacific, 2018-2030 (USD Billion)
Figure 14.157 Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Rest of the World, 2018-2030 (USD Billion)
Figure 14.158 Drug Adherence Enhancement Market for Products Intended for Other Medications, 2018-2030 (USD Billion)
Figure 14.159 Drug Adherence Enhancement Market for Products Intended for Other Medications in North America, 2018-2030 (USD Billion)
Figure 14.160 Drug Adherence Enhancement Market for Products Intended for Other Medications in Europe, 2018-2030 (USD Billion)
Figure 14.161 Drug Adherence Enhancement Market for Products Intended for Other Medications in Asia-Pacific, 2018-2030 (USD Billion)
Figure 14.162 Drug Adherence Enhancement Market for Products Intended for Other Medications in Rest of the World, 2018-2030 (USD Billion)
Figure 14.163 Drug Adherence Enhancement Market for Products Intended for Oral Medications, 2018-2030 (Units, Million)
Figure 14.164 Drug Adherence Enhancement Market for Products Intended for Oral Medications in North America, 2018-2030 (Units, Million)
Figure 14.165 Drug Adherence Enhancement Market for Products Intended for Oral Medications in Europe, 2018-2030 (Units, Million)
Figure 14.166 Drug Adherence Enhancement Market for Products Intended for Oral Medications in Asia-Pacific, 2018-2030 (Units, Million)
Figure 14.167 Drug Adherence Enhancement Market for Products Intended for Oral Medications in Rest of the World, 2018-2030 (Units, Million)
Figure 14.168 Drug Adherence Enhancement Market for Products Intended for Injectables, 2018-2030 (Units, Million)
Figure 14.169 Drug Adherence Enhancement Market for Products Intended for Injectables in North America, 2018-2030 (Units, Million)
Figure 14.170 Drug Adherence Enhancement Market for Products Intended for Injectables in Europe, 2018-2030 (Units, Million)
Figure 14.171 Drug Adherence Enhancement Market for Products Intended for Injectables in Asia-Pacific, 2018-2030 (Units, Million)
Figure 14.172 Drug Adherence Enhancement Market for Products Intended for Injectables in Rest of the World, 2018-2030 (Units, Million)
Figure 14.173 Drug Adherence Enhancement Market for Products Intended for Inhalable Medications, 2018-2030 (Units, Million)
Figure 14.174 Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in North America, 2018-2030 (Units, Million)
Figure 14.175 Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Europe, 2018-2030 (Units, Million)
Figure 14.176 Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Asia-Pacific, 2018-2030 (Units, Million)
Figure 14.177 Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Rest of the World, 2018-2030 (Units, Million)
Figure 14.178 Drug Adherence Enhancement Market for Products Intended for Other Medications, 2018-2030 (Units, Million)
Figure 14.179 Drug Adherence Enhancement Market for Products Intended for Other Medications in North America, 2018-2030 (Units, Million)
Figure 14.180 Drug Adherence Enhancement Market for Products Intended for Other Medications in Europe, 2018-2030 (Units, Million)
Figure 14.181 Drug Adherence Enhancement Market for Products Intended for Other Medications in Asia-Pacific, 2018-2030 (Units, Million)
Figure 14.182 Drug Adherence Enhancement Market for Products Intended for Other Medications in Rest of the World, 2018-2030 (Units, Million)
Figure 15.1 Overall Drug Adherence Enhancement Market, Conservative, Base and Optimistic Scenarios, 2018 and 2030

List of Tables

Table 3.1 Medication Adherence: Methods of Measurement
Table 3.2 Traditional Interventions for Improving Medication Adherence
Table 4.1 Smart Drug Delivery Devices: Information on Developers 
Table 4.2 Smart Drug Delivery Devices: Information on Key Device Specifications
Table 5.1 Smart Accessory Devices: Information on Developers 
Table 5.2 Smart Accessory Devices: Information on Key Device Specifications
Table 5.3 Compliance Packaging Systems: Information on Developers
Table 5.4 Compliance Packaging Systems: Information on Key Specifications
Table 6.1 USFDA Centers for Drugs and Device Approval
Table 6.2 USFDA: Review Timelines
Table 6.3 Regulatory Bodies in EU5 Countries
Table 6.4 SFDA: Regulatory Review Timeline
Table 7.1 Adherium: List of Medications Used with Hailie™ Sensors
Table 7.2 Adherium: Recent Developments and Future Outlook 
Table 7.3 BIOCORP: Recent Developments and Future Outlook
Table 7.4 nGageIT Digital Health: Recent Developments and Future Outlook 
Table 7.5 Proteus Digital Health: Recent Developments and Future Outlook 
Table 7.6 SOOIL Development: Recent Developments and Future Outlook 
Table 7.7 Ypsomed: Specifications of mylife™ YpsoPump®:
Table 7.8 Ypsomed: Recent Developments and Future Outlook 
Table 8.1 AARDEX Group: Recent Developments and Future Outlook 
Table 8.2 Information Mediary: Specifications of Med-ic® Electronic Compliance Monitor®
Table 8.3 Information Mediary: Specifications of eCap™ Electronic Compliance Monitor®
Table 8.4 Information Mediary: Specifications of Med-ic® Coolblue Syringe Pack
Table 8.5 Information Mediary: Specifications of CertiScan® Reader and Software
Table 8.6 Information Mediary: Areas of Application of Med-ic® Smart Label and eCap™
Table 8.7 Information Mediary: Recent Developments and Future Outlook
Table 8.8 MedMinder Systems: Recent Developments and Future Outlook
Table 8.9 Philips: Specifications of spencer®
Table 8.10 Philips: Key Features and Advantages of Philips Automated Medication Dispensing Services
Table 8.11 Philips: Recent Developments and Future Outlook
Table 8.12 Vaica: Specifications of SimpleMed+
Table 8.13 Vaica: Specifications of SimpleMedRX
Table 8.14 Vaica: Specifications of Capsuled™
Table 8.15 Vaica: Specifications of SimpleMed Suit
Table 8.16 Vaica: Recent Developments and Future Outlook
Table 11.1 Drug Adherence Enhancement Market: Funding and Investments, January 2001-August 2018
Table 11.2 Funding and Investment Analysis: Summary of Investments
Table 12.1 Drug Adherence Enhancement: Partnerships and Collaborations, 2010-2018
Table 13.1 Medication Adherence: List of Mobile Applications 
Table 13.2 Medication Adherence with Mobile Applications: List of Publications 
Table 13.3 Medication Adherence with Mobile Applications: List of Clinical Trials
Table 13.4 Medication Adherence with Mobile Applications: Primary and Secondary Endpoint(s), and Study Outcomes of Clinical Trials
Table 16.1 AceAge: Key Highlights
Table 16.2 AdhereTech: Key Highlights
Table 16.3 Amiko Digital Health: Key Highlights
Table 16.4 Cognita Labs: Key Highlights
Table 16.5 etectRx: Key Highlights
Table 16.6 PharmAdva: Key Highlights
Table 16.7 Popit Technologies: Key Highlights
Table 16.8 Wealth Taxi: Key Highlights
Table 17.1 Smart Drug Delivery Devices: Distribution of Developers by Year of Establishment
Table 17.2 Smart Drug Delivery Devices: Distribution of Developers by Geographical Location (Region-wise)
Table 17.3 Smart Drug Delivery Devices: Distribution of Developers by Geographical Location (Country-wise)
Table 17.4 Smart Drug Delivery Devices: Distribution of Developers by Size (Employee Count)
Table 17.5 Smart Drug Delivery Devices: Distribution by Type of Device
Table 17.6 Smart Drug Delivery Devices: Distribution by Mode of Drug Delivery
Table 17.7 Smart Drug Delivery Devices: Distribution by Key Specifications
Table 17.8 Smart Drug Delivery Devices: Distribution by Availability of Audio / Visual Reminders
Table 17.9 Smart Drug Delivery Devices: Distribution by Availability of Connectivity (USB, Bluetooth or Cellular)
Table 17.10 Smart Drug Delivery Devices: Distribution by Availability of Companion Mobile Application
Table 17.11 Smart Drug Delivery Devices: Distribution by Availability of Companion Mobile Application and Companion Web Portal
Table 17.12 Smart Drug Delivery Devices: Distribution by Availability of Companion Mobile Application and Data Storage / Cloud Platform
Table 17.13 Smart Drug Delivery Devices: Distribution by Battery Backup / Rechargeable Battery
Table 17.14 Smart Drug Delivery Devices: Key Players
Table 17.15 Smart Inhalers: Distribution of Developers by Year of Establishment
Table 17.16 Smart Inhalers: Distribution of Developers by Geographical Location
Table 17.17 Smart Inhalers: Distribution of Developers by Size (Employee Count)
Table 17.18 Smart Inhalers: Distribution by Key Device Specifications
Table 17.19 Smart Injectors: Distribution of Developers by Year of Establishment
Table 17.20 Smart Injectors: Distribution of Developers by Geographical Location
Table 17.21 Smart Injectors: Distribution of Developers by Size (Employee Count)
Table 17.22 Smart Injectors: Distribution by Key Device Specifications
Table 17.23 Smart Wearable Injectors: Distribution of Developers by Year of Establishment
Table 17.24 Smart Wearable Injectors: Distribution of Developers by Geographical Location
Table 17.25 Smart Wearable Injectors: Distribution of Developers by Size (Employee Count)
Table 17.26 Smart Wearable Injectors: Distribution by Key Device Specifications
Table 17.27 Smart Pills / Other Smart Devices: Distribution of Developers by Year of Establishment
Table 17.28 Smart Pills / Other Smart Devices: Distribution of Developers by Geographical Location
Table 17.29 Smart Pills / Other Smart Devices: Distribution of Developers by Size (Employee Count)
Table 17.30 Smart Pills / Other Smart Devices: Distribution by Key Device Specifications
Table 17.31 Smart Accessory Devices: Distribution of Developers by Year of Establishment
Table 17.32 Smart Accessory Devices: Distribution of Developers by Geographical Location (Region-wise)
Table 17.33 Smart Accessory Devices: Distribution of Developers by Geographical Location (Country-wise)
Table 17.34 Smart Accessory Devices: Distribution of Developers by Size (Employee Count)
Table 17.35 Smart Accessory Devices: Distribution by Type of Device
Table 17.36 Smart Accessory Devices: Distribution by Key Specifications
Table 17.37 Smart Accessory Devices: Distribution by Availability of Audio / Visual Reminders
Table 17.38 Smart Accessory Devices: Distribution by Availability of Connectivity (USB, Bluetooth, Wi-Fi or Cellular)
Table 17.39 Smart Accessory Devices: Distribution by Availability of Companion Mobile Application
Table 17.40 Smart Accessory Devices: Distribution by Availability of Companion Web Portal
Table 17.41 Smart Accessory Devices: Distribution by Availability of Data Storage / Cloud Platform
Table 17.42 Smart Accessory Devices: Distribution by Availability of Battery Backup / Rechargeable
Table 17.43 Smart Accessory Devices: Key Players
Table 17.44 Smart Medication Dispensers: Distribution of Developers by Year of Establishment
Table 17.45 Smart Medication Dispensers: Distribution of Developers by Geographical Location
Table 17.46 Smart Medication Dispensers: Distribution of Developers by Size (Employee Count)
Table 17.47 Smart Medication Dispensers: Distribution by Key Device Specifications
Table 17.48 Smart Pill Bottles / Caps: Distribution of Developers by Year of Establishment
Table 17.49 Smart Pill Bottles / Caps: Distribution of Developers by Geographical Location
Table 17.50 Smart Pill Bottles / Caps: Distribution of Developers by Size (Employee Count)
Table 17.51 Smart Pill Bottles / Caps: Distribution by Key Device Specifications
Table 17.52 Smart Pill Boxes: Distribution of Developers by Year of Establishment
Table 17.53 Smart Pill Boxes: Distribution of Developers by Geographical Location
Table 17.54 Smart Pill Boxes: Distribution of Developers by Size (Employee Count)
Table 17.55 Smart Pill Boxes: Distribution by Key Device Specifications
Table 17.56 Smart Blister Packs: Distribution of Developers by Year of Establishment
Table 17.57 Smart Blister Packs: Distribution of Developers by Geographical Location
Table 17.58 Smart Blister Packs: Distribution of Developers by Size (Employee Count)
Table 17.59 Smart Blister Packs: Distribution by Key Device Specifications
Table 17.60 Other Smart Devices: Distribution of Developers by Year of Establishment
Table 17.61 Other Smart Devices: Distribution of Developers by Geographical Location
Table 17.62 Other Smart Devices: Distribution of Developers by Size (Employee Count)
Table 17.63 Other Smart Devices: Distribution by Key Device Specifications
Table 17.64 Compliance Packaging Systems: Distribution of Developers by Geographical Location
Table 17.65 Compliance Packaging Systems: Distribution of Developers by Size (Employee Count)
Table 17.66 Compliance Packaging Systems: Distribution by Type of Packaging System
Table 17.67 Compliance Packaging Systems: Distribution by Number of Doses per Pack
Table 17.68 Compliance Packaging Systems: Distribution by Availability of Other Features   
Table 17.69 Adherium: Annual Revenues, FY1516-H1 FY1718 (USD Million)
Table 17.70 BIOCORP: Annual Revenues, 2014-2017 (EUR Million)
Table 17.71 Ypsomed: Annual Revenues, FY1314 – FY1718 (CHF Million)
Table 17.72 Ypsomed: Sales by Business Divisions, FY1718 (CHF Million)
Table 17.73 Philips: Annual Revenues, 2013- H1 2018 (EUR Billion)
Table 17.74 Philips: Revenues by Business Segments, H1 2018 (EUR Billion)
Table 17.75 Overall Product Competitiveness Analysis
Table 17.76 Overall Product Competitiveness Analysis: Distribution of Different Types of Products by Scores
Table 17.77 Funding and Investment Analysis: Cumulative Number of Instances, January 2001 - August 2018
Table 17.78 Funding and Investment Analysis: Cumulative Amount Invested, January 2001-August 2018 (USD Million)
Table 17.79 Funding and Investment Analysis: Distribution by Type of Funding, January 2001 - August 2018
Table 17.80 Funding and Investment Analysis: Distribution of Total Amount Invested by Type of Funding, January 2001 - August 2018 (USD Million)
Table 17.81 Funding and Investment Analysis: Summary of Investments, January 2001-August 2018 (USD Million)
Table 17.82 Funding and Investment Analysis: Distribution of Number of Funding Instances by Year of Investment and Major Device Categories, January 2001- August 2018
Table 17.83 Funding and Investment Analysis: Distribution of Number of Funding Instances by Type of Funding and Major Device Categories, January 2001-August 2018
Table 17.84 Funding and Investment Analysis: Distribution of Amount Invested by Year of Investment and Major Device Categories, January 2001- August 2018
Table 17.85 Funding and Investment Analysis: Most Active Players in terms of Number of Instances, January 2001-August 2018
Table 17.86 Funding and Investment Analysis: Most Active Players in Terms of Amount Raised (USD Million), January 2001-August 2018
Table 17.87 Funding and Investment Analysis: Most Active Investors
Table 17.88 Funding and Investment Summary
Table 17.89 Partnerships and Collaborations: Distribution by Year, 2010-2018
Table 17.90 Partnerships and Collaborations: Distribution by Type of Partnership
Table 17.91 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
Table 17.92 Partnerships and Collaborations: Most Active Players
Table 17.93 Partnerships and Collaborations: Distribution by Type and Year of Partnership
Table 17.94 Partnerships and Collaborations: Distribution by Type and Geographical Presence of Companies
Table 17.95 Partnerships and Collaborations: Regional Distribution
Table 17.96 Medication Adherence Clinical Trial Publications for Software Applications: Distribution by Therapeutic Areas
Table 17.97 Global Drug Adherence Enhancement Market, Conservative, Base and Optimistic Scenarioss, Scenarios2018-2030 (USD Billion)
Table 17.98 Drug Adherence Enhancement Market for Smart Drug Delivery Devices, Conservative, Base and Optimistic Scenarios, Scenarios2018-2030 (USD Billion)
Table 17.99 Drug Adherence Enhancement Market for Smart Accessory Devices, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.100 Drug Adherence Enhancement Market for Other Type of Devices, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.101 Global Drug Adherence Enhancement Market, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.102 Digital Drug Adherence Enhancement Market for Smart Drug Delivery Devices, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.103 Drug Adherence Enhancement Market for Smart Accessory Devices, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.104 Drug Adherence Enhancement Market for Other Type of Devices, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.105 Drug Adherence Enhancement Market in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.106 Drug Adherence Enhancement Market in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.107 Drug Adherence Enhancement Market in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.108 Drug Adherence Enhancement Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.109 Drug Adherence Enhancement Market for Smart Inhalers, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.110 Drug Adherence Enhancement Market for Smart Inhalers in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.111 Drug Adherence Enhancement Market for Smart Inhalers in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.112 Drug Adherence Enhancement Market for Smart Inhalers in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.113 Drug Adherence Enhancement Market for Smart Inhalers in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.114 Drug Adherence Enhancement Market for Smart Injectors, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.115 Drug Adherence Enhancement Market for Smart Injectors in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.116 Drug Adherence Enhancement Market for Smart Injectors in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.117 Drug Adherence Enhancement Market for Smart Injectors in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.118 Drug Adherence Enhancement Market for Smart Injectors in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.119 Drug Adherence Enhancement Market for Smart Wearable Injectors, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.120 Drug Adherence Enhancement Market for Smart Wearable Injectors in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.121 Digital Drug Adherence Enhancement Market for Smart Wearable Injectors in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.122 Drug Adherence Enhancement Market for Smart Wearable Injectors in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.123 Drug Adherence Enhancement Market for Smart Wearable Injectors in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.124 Drug Adherence Enhancement Market for Smart Pills, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.125 Drug Adherence Enhancement Market for Smart Pills in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.126 Drug Adherence Enhancement Market for Smart Pills in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.127 Drug Adherence Enhancement Market for Smart Pills in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.128 Drug Adherence Enhancement Market for Smart Pills in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.129 Drug Adherence Enhancement Market for Smart Medication Dispensers, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.130 Drug Adherence Enhancement Market for Smart Medication Dispensers in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.131 Drug Adherence Enhancement Market for Smart Medication Dispensers in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.132 Drug Adherence Enhancement Market for Smart Medication Dispensers in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.133 Drug Adherence Enhancement Market for Smart Medication Dispensers in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.134 Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.135 Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 
(USD Billion)
Table 17.136 Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD 
Billion)
Table 17.137 Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 
(USD Billion)
Table 17.138 Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-
2030 (USD Billion)
Table 17.139 Drug Adherence Enhancement Market for Smart Blister Packs, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.140 Drug Adherence Enhancement Market for Smart Blister Packs in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.141 Drug Adherence Enhancement Market for Smart Blister Packs in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.142 Drug Adherence Enhancement Market for Smart Blister Packs in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.143 Drug Adherence Enhancement Market for Smart Blister Packs in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.144 Drug Adherence Enhancement Market for Other Type of Products, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.145 Drug Adherence Enhancement Market for Other Type of Products in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.146 Drug Adherence Enhancement Market for Other Type of Products in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.147 Drug Adherence Enhancement Market for Other Type of Products in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.148 Drug Adherence Enhancement Market for Other Type of Products in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.149 Drug Adherence Enhancement Market for Smart Inhalers, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.150 Drug Adherence Enhancement Market for Smart Inhalers in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.151 Drug Adherence Enhancement Market for Smart Inhalers in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.152 Drug Adherence Enhancement Market for Smart Inhalers in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.153 Drug Adherence Enhancement Market for Smart Inhalers in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.154 Drug Adherence Enhancement Market for Smart Injectors, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.155 Drug Adherence Enhancement Market for Smart Injectors in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.156 Drug Adherence Enhancement Market for Smart Injectors in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.157 Drug Adherence Enhancement Market for Smart Injectors in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.158 Drug Adherence Enhancement Market for Smart Injectors in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.159 Drug Adherence Enhancement Market for Smart Wearable Injectors, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.160 Drug Adherence Enhancement Market for Smart Wearable Injectors in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.161 Digital Drug Adherence Enhancement Market for Smart Wearable Injectors in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.162 Drug Adherence Enhancement Market for Smart Wearable Injectors in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.163 Drug Adherence Enhancement Market for Smart Wearable Injectors in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.164 Drug Adherence Enhancement Market for Smart Pills, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.165 Drug Adherence Enhancement Market for Smart Pills in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.166 Drug Adherence Enhancement Market for Smart Pills in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.167 Drug Adherence Enhancement Market for Smart Pills in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.168 Drug Adherence Enhancement Market for Smart Pills in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.169 Drug Adherence Enhancement Market for Smart Medication Dispensers, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.170 Drug Adherence Enhancement Market for Smart Medication Dispensers in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.171 Drug Adherence Enhancement Market for Smart Medication Dispensers in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.172 Drug Adherence Enhancement Market for Smart Medication Dispensers in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.173 Drug Adherence Enhancement Market for Smart Medication Dispensers in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.174 Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.175 Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.176 Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.177 Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.178 Drug Adherence Enhancement Market for Smart Pill Bottles / Caps and Pill Boxes in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.179 Drug Adherence Enhancement Market for Smart Blister Packs, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.180 Drug Adherence Enhancement Market for Smart Blister Packs in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.181 Drug Adherence Enhancement Market for Smart Blister Packs in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.182 Drug Adherence Enhancement Market for Smart Blister Packs in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.183 Drug Adherence Enhancement Market for Smart Blister Packs in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.184 Drug Adherence Enhancement Market for Other Type of Products, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.185 Drug Adherence Enhancement Market for Other Type of Products in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.186 Drug Adherence Enhancement Market for Other Type of Products in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.187 Drug Adherence Enhancement Market for Other Type of Products in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.188 Drug Adherence Enhancement Market for Other Type of Products in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.189 Drug Adherence Enhancement Market for Metabolic Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.190 Drug Adherence Enhancement Market for Metabolic Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.191 Drug Adherence Enhancement Market for Metabolic Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.192 Drug Adherence Enhancement Market for Metabolic Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.193 Drug Adherence Enhancement Market for Metabolic Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.194 Drug Adherence Enhancement Market for Cardiovascular Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.195 Drug Adherence Enhancement Market for Cardiovascular Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.196 Drug Adherence Enhancement Market for Cardiovascular Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.197 Drug Adherence Enhancement Market for Cardiovascular Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.198 Drug Adherence Enhancement Market for Cardiovascular Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.199 Drug Adherence Enhancement Market for Respiratory Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.200 Drug Adherence Enhancement Market for Respiratory Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.201 Drug Adherence Enhancement Market for Respiratory Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.202 Drug Adherence Enhancement Market for Respiratory Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.203 Drug Adherence Enhancement Market for Respiratory Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.204 Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.205 Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.206 Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.207 Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Asia-Pacific, Conservative, Base and Optimistic 
Scenarios, 2018-2030 (USD Billion)
Table 17.208 Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.209 Drug Adherence Enhancement Market for Other Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.209 Drug Adherence Enhancement Market for Other Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.210 Drug Adherence Enhancement Market for Other Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.211 Drug Adherence Enhancement Market for Other Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.212 Drug Adherence Enhancement Market for Other Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.213 Drug Adherence Enhancement Market for Metabolic Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.214 Drug Adherence Enhancement Market for Metabolic Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.215 Drug Adherence Enhancement Market for Metabolic Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.216 Drug Adherence Enhancement Market for Metabolic Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.217 Drug Adherence Enhancement Market for Metabolic Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.218 Drug Adherence Enhancement Market for Cardiovascular Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.219 Drug Adherence Enhancement Market for Cardiovascular Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.220 Drug Adherence Enhancement Market for Cardiovascular Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.221 Drug Adherence Enhancement Market for Cardiovascular Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.222 Drug Adherence Enhancement Market for Cardiovascular Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.223 Drug Adherence Enhancement Market for Respiratory Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.224 Drug Adherence Enhancement Market for Respiratory Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.225 Drug Adherence Enhancement Market for Respiratory Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.226 Drug Adherence Enhancement Market for Respiratory Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.227 Drug Adherence Enhancement Market for Respiratory Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.228 Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.229 Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in North America, Conservative, Base and Optimistic 
Scenarios, 2018-2030 (Units, Million)
Table 17.230 Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.231 Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.232 Drug Adherence Enhancement Market for Neurological and Central Nervous System-Related Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.233 Drug Adherence Enhancement Market for Other Disorders, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.234 Drug Adherence Enhancement Market for Other Disorders in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.235 Drug Adherence Enhancement Market for Other Disorders in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.236 Drug Adherence Enhancement Market for Other Disorders in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.237 Drug Adherence Enhancement Market for Other Disorders in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.238 Drug Adherence Enhancement Market for Products Intended for Oral Medications, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.239 Drug Adherence Enhancement Market for Products Intended for Oral Medications in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.240 Drug Adherence Enhancement Market for Products Intended for Oral Medications in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.241 Drug Adherence Enhancement Market for Products Intended for Oral Medications in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.242 Drug Adherence Enhancement Market for Products Intended for Oral Medications in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.243 Drug Adherence Enhancement Market for Products Intended for Injectables, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.244 Drug Adherence Enhancement Market for Products Intended for Injectables in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.245 Drug Adherence Enhancement Market for Products Intended for Injectables in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.246 Drug Adherence Enhancement Market for Products Intended for Injectables in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.247 Drug Adherence Enhancement Market for Products Intended for Injectables in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.248 Drug Adherence Enhancement Market for Products Intended for Inhalable Medications, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.249 Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.250 Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.251 Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.252 Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.253 Drug Adherence Enhancement Market for Products Intended for Other Medications, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.254 Drug Adherence Enhancement Market for Products Intended for Other Medications in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.255 Drug Adherence Enhancement Market for Products Intended for Other Medications in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.256 Drug Adherence Enhancement Market for Products Intended for Other Medications in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.257 Drug Adherence Enhancement Market for Products Intended for Other Medications in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (USD Billion)
Table 17.258 Drug Adherence Enhancement Market for Products Intended for Oral Medications, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.259 Drug Adherence Enhancement Market for Products Intended for Oral Medications in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.260 Drug Adherence Enhancement Market for Products Intended for Oral Medications in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.261 Drug Adherence Enhancement Market for Products Intended for Oral Medications in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.262 Drug Adherence Enhancement Market for Products Intended for Oral Medications in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.263 Drug Adherence Enhancement Market for Products Intended for Injectables, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.264 Drug Adherence Enhancement Market for Products Intended for Injectables in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.265 Drug Adherence Enhancement Market for Products Intended for Injectables in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.266 Drug Adherence Enhancement Market for Products Intended for Injectables in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.267 Drug Adherence Enhancement Market for Products Intended for Injectables in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.268 Drug Adherence Enhancement Market for Products Intended for Inhalable Medications, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.269 Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 
(Units, Million)
Table 17.270 Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.271 Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.272 Drug Adherence Enhancement Market for Products Intended for Inhalable Medications in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.273 Drug Adherence Enhancement Market for Products Intended for Other Medications, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.274 Drug Adherence Enhancement Market for Products Intended for Other Medications in North America, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.275 Drug Adherence Enhancement Market for Products Intended for Other Medications in Europe, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.276 Drug Adherence Enhancement Market for Products Intended for Other Medications in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)
Table 17.277 Drug Adherence Enhancement Market for Products Intended for Other Medications in Rest of the World, Conservative, Base and Optimistic Scenarios, 2018-2030 (Units, Million)

List of Companies

The following companies have been mentioned in the report:

  1. 3M
  2. 5AM Ventures
  3. 7wire Ventures
  4. 91streets Media Technologies
  5. AARDEX Group
  6. AARP
  7. Abbott
  8. Abiogenix
  9. AceAge
  10. Acintyo
  11. Acta Distribution
  12. ActiveCare
  13. Adams Street Partners
  14. AdhereTech
  15. Adherium
  16. Administración Nacional de Medicamentos, Alimentosy Tecnología Médica
  17. Advent Venture Partners
  18. Aerobit Health
  19. AeroSonix
  20. Agência Nacional de Vigilância Sanitária (National Health Surveillance Agency)
  21. Aguettant
  22. Air Liquide Healthcare
  23. AIRBRIO
  24. Airnest
  25. Allscripts
  26. Altran
  27. Amarutek
  28. Amazon
  29. AMC Health
  30. American Academy of Allergy, Asthma and Immunology
  31. American Heart Association
  32. Amerigroup
  33. Amgen
  34. Amiko Digital Health
  35. ANTARGYAN CLOUDWORKS
  36. ApnaCare India
  37. Apollo Diabetes Care Management
  38. Apolotus Health Solution
  39. Apoteket
  40. App Singularity
  41. AppAttic
  42. Appgraid Apps
  43. AppQuik
  44. AppTrailz
  45. Aptar Pharma
  46. Area9 Innovation
  47. Arthur Health
  48. Artmedus
  49. ARTORG Center
  50. AS PHARM SOFT
  51. Asheville Angels
  52. Asho Soft Tech
  53. Asset Management Ventures
  54. Asthma and Respiratory Foundation New Zealand
  55. AstraZeneca
  56. AT&T
  57. Aterica Digital Health
  58. August Faller Group
  59. Auriga Partners
  60. Australasian Medical & Scientific
  61. Austrian Chamber of Pharmacists
  62. Automated Security Alert
  63. Aventyn
  64. Avery Dennison Medical Solutions
  65. Avnet Integrated Solutions
  66. Baviux
  67. Bayer
  68. Becton Dickinson
  69. BERG
  70. Bigfoot Biomedical
  71. BioAdvance
  72. BioAssist
  73. BIOCORP
  74. BioMark Health
  75. BioScience Managers
  76. BIVA
  77. BlackPearls
  78. Blackberry
  79. Blueprint Health
  80. Boehringer Ingelheim
  81. Bosch
  82. Brain Tech
  83. Brainovations Education Excellence
  84. Breed Reply
  85. Butterfly Ventures
  86. C-Square Info Solutions
  87. C3HealthLink
  88. caiocrol
  89. California HealthCare Foundation
  90. California Highlands Addiction Treatment
  91. Cambridge Enterprise
  92. Cambridge Consultants
  93. Canada Innovation Acceleration Investment
  94. Capital Angels
  95. Capital Royalty Partners II
  96. Cardinal Health
  97. CareCentra
  98. CareConsult
  99. CareZone
  100. Catalent Pharma Solutions
  101. Celgene
  102. Cellnovo
  103. Cenduit
  104. Centers for Disease Control and Prevention
  105. Centers for Medicare & Medicaid Services
  106. Central Drugs Standard Control Organization
  107. Centric Health
  108. Chalmers Ventures
  109. CheckTheMeds Technology
  110. Children's Hospital of Philadelphia
  111. China Food and Drug Administration
  112. CHORDAS
  113. Chronicare
  114. Cigna Health Insurance
  115. Cincinnati Children's Hospital Medical Center
  116. Circadian Design
  117. Clifton R Farris
  118. CML Advocates Network
  119. Cognita Labs
  120. Cognitive Healthcare
  121. Cohero Health
  122. Colbert Packaging
  123. Comisión Federal para la Protección contra Riesgos Sanitarios
  124. Common Sensing
  125. Community Care Network of Virginia
  126. Companion Medical
  127. Compliance Meds Technologies
  128. Confrérie Clinique
  129. Connecticut Children's Medical Center
  130. Core Mobile
  131. Credit Agricole Private Equity
  132. Crux Product Design
  133. CSL Behring
  134. C Square Info Solutions
  135. CUCO Health
  136. CuePath Innovation
  137. Curatio
  138. Curis
  139. Cyft
  140. DayaMed
  141. Debiotech
  142. Decision Machines
  143. DeepBench
  144. Delphi Ventures
  145. Desert Oasis Healthcare
  146. DeskShare
  147. Dexcom
  148. Diabeloop
  149. Diasend
  150. Digital Pharmacist
  151. Diplomat Pharmacy
  152. Disetronic Group
  153. Dispill-USA
  154. DistriMedic
  155. DocRoSh Health
  156. Domain Associates
  157. Dosecast
  158. DoseCue
  159. DoseSmart
  160. DOTh Solutions
  161. Douglas Pharmaceuticals
  162. Drug Package
  163. Duke University
  164. DYN Diagnostics
  165. EcoloPharm
  166. Edmond de Rothschild
  167. E Ink
  168. Elcam Drug Delivery Devices (E3D)
  169. Eli Lilly
  170. Elkstone Capital Partners
  171. EMedStore Pharma IT
  172. emocha Mobile Health
  173. Emperra E-Health Technologies
  174. Enable Injections
  175. Enercon Technologies
  176. EnvoyHealth
  177. Essex Woodlands
  178. etectRx
  179. ETHIO APPS
  180. Eularis
  181. European Investment Bank
  182. European Medicines Agency
  183. Evalan
  184. Everwell Health Solutions
  185. Everwin Precision Technology
  186. Evondos
  187. Excell Partners
  188. Experts in Communications and Connectivity Technology (ECCT)
  189. Express Scripts
  190. Fagor Healthcare
  191. Fedefarma
  192. Fidelity International
  193. FindAir
  194. The Finnish Funding Agency for Technology and Innovation
  195. Fletcher Spaght Ventures
  196. Flex
  197. Forbion Capital Partners
  198. Frost & Sullivan
  199. GalileoMD
  200. Gecko Health Innovations
  201. GenieMD
  202. Genome BC
  203. GIS Strategic Ventures
  204. GlaxoSmithKline
  205. Global Emerging Markets Group
  206. Gloria Pharmaceuticals
  207. GlucoRx
  208. GoSmart
  209. GoodCare Pharma
  210. GoodRx
  211. GoodVent Beteiligungsmanagement
  212. H&T Presspart
  213. H&Y Apps
  214. Hackensack Meridian Health
  215. HAP Innovations
  216. Haselmeier
  217. HCL Technologies
  218. Health Bot
  219. Health Canada
  220. Health Care Originals
  221. Health Department of Oslo
  222. Health Mission
  223. Health Monitor
  224. HealthBeacon
  225. Healthbox
  226. HealthCare Ventures
  227. Healthcom
  228. Healtheoz
  229. Healthio
  230. HealthPrize Technologies
  231. Health's Angel
  232. Heitkamp & Thumann Group
  233. Helmer Scientific
  234. Hepatitis Victoria
  235. HERO Health
  236. Hexoskin
  237. Hikma Ventures
  238. Home Diagnostics
  239. HP Labs
  240. HTC
  241. Human API
  242. Humana
  243. IAP Labs
  244. IDEAL LIFE
  245. ImageWare Systems
  246. ImagineCare
  247. Immunex
  248. Information Mediary
  249. Innospence
  250. Innovation Zed
  251. INRange Systems
  252. Inspirit Innovations
  253. Insulin Pump Hellas
  254. Intelligent Devices SEZC
  255. Intelligent Product Solutions
  256. Intent Solutions
  257. International Diabetes Federation
  258. International Federation of Pharmaceutical Manufacturers and Associations
  259. Intigate Technologies
  260. Investitionsbank des Landes Brandenburg
  261. Irody
  262. IRWAA
  263. iSense
  264. ITmedicus
  265. Itochu
  266. IVAX
  267. Jabil
  268. Janssen Pharmaceutica
  269. JDRF
  270. Jiangsu Delfu Medical Device
  271. Jones Packaging
  272. Joslin Diabetes Center
  273. Journey Health Labs
  274. JVS Technologies
  275. Kaiser Permanente Ventures
  276. KCRise Fund
  277. Keystone Folding Box
  278. Konkuk University
  279. Korl Medical Center
  280. Kreos Capital
  281. K-svets
  282. Kuwait Investment Authority
  283. Life Integrating Technologies and Experiences (LITE)
  284. Life Sciences Angel Network
  285. LifeMatters
  286. LloydsPharmacy
  287. Lohmann Therapie Systeme
  288. lool Ventures
  289. Lowcountry Angels
  290. LoyAlerts
  291. LSDinfotech
  292. Luz Saúde
  293. M Ventures
  294. M2M Datasmart
  295. Maangata Apps
  296. Maccabi Healthcare Services
  297. Mail-Meds
  298. Maj Invest Equity
  299. Manchac Technologies
  300. Mango Health
  301. Manrex
  302. Manyeta
  303. MAP Health Management
  304. Marketaro
  305. MassChallenge
  306. Maxerence
  307. McKesson
  308. MeadWestvaco
  309. MedApps
  310. MedControl Technologies
  311. MedCrypt
  312. Medexpert
  313. Medical International Research
  314. Medical Research Institute of New Zealand
  315. Medical Specialties Australia
  316. Medication Solutions
  317. Medicine-On-Time
  318. Medico Pak
  319. Medicom Innovation Partner
  320. MedicPen
  321. Medimate
  322. Medipense
  323. Medisafe
  324. MedMinder Systems
  325. Medocity
  326. MedPak Pharmacy
  327. MedReady
  328. MedSmart
  329. Medtronic
  330. Medtrum
  331. MENA Apps
  332. Merck
  333. Metro Health
  334. Mevia
  335. MicroHealth
  336. Ministry of Food and Drug Safety
  337. Ministry of Health, Labour and Welfare
  338. MivaTek Smart Connect
  339. Molina Healthcare
  340. Montuno Software
  341. Mount Sinai Health System
  342. Movi
  343. MphRx
  344. Multiframes
  345. Mylan
  346. MyMeds
  347. MyTherapy
  348. NantHealth
  349. Nath IT Solutions
  350. National Competent Authority
  351. National Consumers League
  352. National Institutes of Health
  353. National Institute of Mental Health (NIMH)
  354. Navia Life Care
  355. NaviMed
  356. NBGI Ventures
  357. NECTEC
  358. Nemera
  359. NESTA
  360. Nestlé Health Science
  361. New Directions Technology Consulting
  362. New World Health
  363. New Zealand Medical & Scientific
  364. NexusLink Services
  365. nGageIT Digital Medicine
  366. Noble International
  367. NOPII
  368. Novalab Ibérica
  369. Novartis
  370. Novo Nordisk
  371. Now Healthcare Group
  372. NPS MedicineWise
  373. Octopus Ventures
  374. Office of the National Coordinator for Health Information Technology Omnicell
  375. Omron Healthcare
  376. One Drop
  377. Onward Care Technologies
  378. Oracle Health Sciences
  379. Orbita
  380. ORI Healthcare Fund
  381. Otsuka Pharmaceutical
  382. Oxford Finance
  383. Oyster Capital Partners
  384. P5 Health Ventures
  385. Palladio Group
  386. Parata Systems
  387. Partners HealthCare
  388. PatientPartner
  389. PBJ Capital
  390. Pear Therapeutics
  391. Pegasystems
  392. Peppermint VenturePartners
  393. PhableCare
  394. Pharmacell Medication Systems
  395. Pharmaceutical and Medical Devices Agency
  396. PharmAdva
  397. PharmaSens
  398. PharmRight
  399. Philips
  400. Phillips-Medisize
  401. Phoenix Healthcare
  402. Picomol Healthcare
  403. PillDrill
  404. Pillo Health
  405. PillPack
  406. Pitango Venture Capital
  407. Play-it Health
  408. PMA Pharmacy
  409. Poliweb Graphics
  410. Popit
  411. Portal Instruments
  412. Practo
  413. Prescription Notification Group
  414. Prescription Solutions
  415. ProCare Rx
  416. Propeller Health 
  417. Proteus Digital Health
  418. PRPL
  419. Qualcomm Life
  420. Quantum Pharmaceutical
  421. Quido Healthcare Services
  422. QuiO Technologies
  423. Quizora Media
  424. Raffles Medical Group
  425. Ramtin Software Solutions
  426. Raneem Technologies
  427. Recovery Centers of America
  428. RemindTrac
  429. Renata
  430. Research Institute of the McGill University Health Centre
  431. Resolve Digital Health
  432. Respia
  433. Rex Medical
  434. Risk Cooperative
  435. Robert Bosch Venture Capital
  436. Roche
  437. RockTenn
  438. Rubin Medical
  439. RxAdvance
  440. RxNetworks  
  441. RXVIP Concierge
  442. Safeguard Scientifics
  443. Safeway
  444. Sagentia
  445. Samsung
  446. Samsung NEXT
  447. Sanner Group
  448. Sanofi
  449. Sanofi-Sunrise
  450. Saudi Food and Drug Authority
  451. Schreiner MediPharm
  452. SCRA Technology
  453. Second Technology Capital Investors
  454. SentiCare
  455. Seoul National University
  456. Serendipity Partners
  457. SHL Group
  458. Silicon Valley Bank
  459. Simplified APP Solutions
  460. Sino Portfolio
  461. Sinwho
  462. SmarterHealth TechServe
  463. Smartgateways
  464. Smiths Medical
  465. Smooth Apps Studio
  466. SMRxT
  467. Social Capital
  468. Soft Industry Alliance
  469. Sonceboz
  470. SOOIL Development
  471. South Carolina Angel Network
  472. Spartanburg Angels
  473. Spring Ridge Ventures
  474. Sprint
  475. Spyzar Studios
  476. SR One
  477. St. Helena Health
  478. St. Jude Medical
  479. STAAR Alert
  480. Sunrise Labs
  481. SuperAndroidApp
  482. Swanhill Capital
  483. Syqe Medical
  484. Takeda Pharmaceutical
  485. Tandem Diabetes Care
  486. TCGRx
  487. Techizer Tech Solutions
  488. Tekes
  489. TerraNovita
  490. Teva Pharmaceutical
  491. The Carlyle Group
  492. The Cyto Cord Group
  493. The Kroger
  494. Therapeutic Goods Administration
  495. Three Leaf Ventures
  496. Tidepool
  497. Tillotts Pharma
  498. TimerCap
  499. Tinylogics
  500. Tonghua Dongbao Pharmaceutical
  501. TowerView Health
  502. TPG Biotech
  503. Triad HealthCare Network
  504. Tricella
  505. Trinnovate Ventures
  506. TriVentures
  507. TypeZero Technologies
  508. UNICUS HealthReach
  509. United Family Healthcare
  510. United States Food and Drug Administration
  511. UnitedHealthcare
  512. University of Cambridge
  513. University of Arkansas for Medical Sciences
  514. University of Toronto
  515. University of Pittsburgh Medical Center
  516. Urtech Manufacturing
  517. Vaica
  518. Valtronic
  519. Vectura Group
  520. Verizon Investments
  521. Virbac
  522. Vishnu Global Services
  523. Vitalus Health
  524. Walgreens
  525. Waterline Ventures
  526. Wcre8tive App Developer
  527. Wealth Taxi
  528. Web Coast Apps
  529. Welkin Health
  530. West Pharmaceutical Services
  531. WestRock
  532. Whisper Arts
  533. WMM
  534. World Allergy Organization
  535. World Health Organization
  536. WorldMedic
  537. Wyeth-Ayerst Pharmaceuticals
  538. Xcenda
  539. Xhale
  540. Ximedica
  541. XINK Laboratories
  542. YOURmeds
  543. YPSOMED
  544. Zaffre Investments
  545. Zibdy
  546. Zipit Wireless

PRICING DETAILS

USD 3,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com

This site uses cookies for better browsing experience  Accept

Copyright © 2023 Roots Analysis. All Rights Reserved.